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Extracts of the African potato have long been believed to have anti-cancer properties. The 
aim of the current research was to isolate hypoxoside (HYP) from Hypoxis hemerocallidea 
(African potato) and synthesize the dimethyl (DMH) and decaacetyl (DAH) derivatives and 
to test their selective cytotoxicity on a model consisting of a normal (MCF10A) and 
premalignant, invasive breast epithelial cells (MCF10A-NeoT). 
 
Hypoxoside was extracted from the H. hemerocallidea corms using ethanol, purified using a 
C-18 reverse phase column and the compound examined by nuclear magnetic resonance 
(NMR) spectroscopy and high-resolution mass spectrometry and found to be of high purity. 
This was also the case for the synthesized compounds. To assess possible selective effects 
(cytotoxicity) of derivatized and underivatized hypoxoside, effects on the metabolism of 
premalignant and normal cells were assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Effects on cell 
number (total counts) and cell death [trypan blue and propidium iodide (PI) staining for dead 
cells versus a lack of staining for live cells] were, thereafter, assessed. Imaging of live 
adherent cells was also carried out using acridine orange (AO) and PI for live and dead cells 
(respectively). Propidium iodide staining of detached cells was carried out for flow 
cytometric determination of cell death (PI indicating early apoptotic or late apoptotic/necrotic 
cells). 
 
After treatment of normal (MCF10A) breast epithelial cells and premalignant cHa-ras-
transfected (MCF10A-NeoT) derivative breast epithelial cells with HYP, DMH and the DAH 
derivative, the MTS assay and the Duncan‟s multiple range, analysis of variance (ANOVA) 
post hoc analysis of the MTS results revealed that only the 150 and 300 M DAH derivative 
had a statistically significant effect on the metabolic activity of the abnormal cell line relative 
to the dimethyl sulfoxide (DMSO) and revealed no significant effect on the normal MCF-
10A cell line after treatment with any of the test compounds. Supravital PI staining of 
adherent cells seemed to indicate a far higher rate of induction of cell death in abnormal cells 
than evident in the MTS assay and the PI-based flow cytometry or the trypan blue exclusion 




Total cell counts, show that HYP and its derivatives appear to increase both cancer and 
normal cell proliferation significantly, except in the case of DAH at 150 and 300 µM in the 
MCF10A-NeoT, without affecting the MCF-10A cell line. The trypan blue method for 
detection of cell death, together with total cell counts, the Duncan‟s analysis of MTS results 
and a 24 hour exposure to test compounds, seems to constitute an optimal system for drug 
screening and indicates the statistically significant selective toxicity of the DAH compound at 
150 and 300 µM in the MCF10A-NeoT, suggesting that the DAH derivative at 150 and 300 
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Cancer is a disease in which cell growth becomes uncontrolled, and subsequently an 
imbalance between cell proliferation and apoptosis results (Cancer facts and figures, 2009). If 
proteases are upregulated and the cells are invasive, they also spread to other parts of the 
body through lymph or blood. The South African Medical Research Council reported that, in 
2003, cancer was ranked as the fourth leading death-causing disease in South Africa (Bello et 
al., 2011). This disease has been a leading cause of death worldwide and in 2008, around 
12.7 million cancer cases were reported and 7.6 million deaths were due to cancer. The 
economic state of the country has a major impact on the seriousness of the cancer burden. 
The developed countries have more cases but fewer deaths as more advanced ways of 
detecting, treating and funding cancer treatment in such countries (Jemal et al., 2011).  
The complexity of the disease is reflected by the fact that more than 100 distinct types and 
subtypes of tumours within a specific organ have previously been identified (Hanahan and 
Weinberg, 2000). Cancers may be categorized into five different classes named according to 
the location in the body in which they develop. Carcinomas are derived from epithelial cells 
and include lung, breast, prostate and colon cancers, and about 90% of cancers belong to this 
class. Sarcomas are derived from muscle and connective tissues while germ line tumours are 
from totipotent cells which are found in testes and ovaries. Lymphomas and leukaemia are 
derived from the hematopoietic cells, while blastomas are derived from the immature 
embryonic tissue, most commonly in children (WHO, 2006). Blastomas arise from a single 
cell that is transformed from a normal to a cancer cell via multistage processes. The leading 
groups resulting in terminal cancers are cancers of the lung, stomach, and breast, liver and 
colon (WHO, 2006).  
A tumour usually exhibits uncontrollable cell growth and can either be benign or malignant. 
Malignant metastatic tumours or “neoplasm” can invade normal tissues and spread to distant 
body sites, while the benign tumours remain confined in their original location (Cooper, 
1993). The tumour formed by the malignant cells generally cannot grow beyond 2 mm in 
diameter without developing a new vasculature system so as to be nourished (Bluff et al., 
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2008). This pr ocess is called “angiogenesis” and is very im portant for the growth of the  
tumour. Tumour cells with the capacity to migrate and metastasize m ay subsequently g ain 
access to the bloodstream to migrate and form secondary tumours at distant sites (Bluff et al., 
2008) (Figure 1.1).  
 
Figure 1.1: Angiogenesis and metastatic stages. 
 
There is a cascade of events that the tumour cells go through before it can metastasize. When 
cells grow into benign tumours in the epithelium cells, genetic alterations permit cells to break 
through the basal lamina and invade into capillaries. Once they reach the capillaries they can 
travel to any distant site in the body. The tumour cells invade the distant tissues by adhering to 
the capillary walls and invading into the surrounding tissues, where they can proliferate and 
become transformed in to many t ypes o f tu mours due to en vironment and g enetic mutation 
(Alberts et al., 2002). 
Cells grow as a benign 
tumour in epithelium cells 
Basal lamina 
Connective tissues 
Break through basal lamina Invade capillary 
Capillary Travel through bloodstream (less 
than 1 in 1000 cells will survive 
to form metastases) 
Adhere to blood vessels wall in liver 
Escape from blood vessel 
(extravasation) 
Proliferate to form metastasis in liver 
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1.1.1. Causes and prevention of cancer 
Cancer can be diagnosed in anyone at any time but the risks of developing cancer increases 
with age. About 77% of all cancers are diagnosed in people over the age of 55 years (Cancer 
facts and figures, 2009) and arise mainly due to the mutation in the genetic material resulting 
in transformation. Transformation usually arises due to mutations affecting three classes of 
genes: DNA repair genes (DRG), tumour suppressor genes (TSG) or genes involved in cell 
growth (GG). DRG usually prevent accumulation of genetic mistakes, TSG genes usually 
restraining cell growth and division, and the GG genes usually regulate cell growth and 
division (Hanahan and Weinberg, 2000). Together or in isolation, these contribute to a 
progression towards the malignant, invasive phenotype, the focus of the current study as the 
invasive tumours tend to cause the highest rate of mortality. 
p53 is a commonly mutated tumour suppressor gene guarding the fidelity of replication of the 
genomic DNA upon cell division and regulating cell division. Random mutations eventually 
allow progression and select for cells of increased malignancy as increasing numbers of 
mutations escape removal (Spandidos et al., 1999). One of the later mutations associated with 
invasion is the Val-12 mutation in the normal H-Ras signalling protein, a protein that controls 
the cell division, proliferation and phenotype, switching on a more migratory, invasive 
phenotype and switching off a polarized non-migratory, normal epithelial-type phenotype 
(Ota et al., 2009). This specific combination of mutations facilitates invasion, increasing cell 
proliferation and uncontrolled replication (Bluff et al., 2008) and hence forms a focus of the 
current study. 
Mutations can initially be due to internal factors such as inherited mutations, hormones, 
immune conditions, and mutations that occur due to metabolic imbalances (Cancer facts and 
figures, 2009). External factors involve smoking cigarettes, alcohol consumption, asbestos-
inhalation, ultraviolet light or ionizing radiation exposure, as well as exposure to drinking 
water contaminated with chemicals such as arsenic, and some infectious organisms (Ma and 
Yu, 2006). The infections associated with cancer development involve viruses such as human 
papilloma virus (HPV), for cervical cancer, human immune deficiency virus (HIV) for 
Karposi sarcoma, hepatitis B for liver cancer; bacteria such as Helicobacter pylori for 
stomach cancer, and parasites such as schistosomiasis for bladder cancer (WHO, 2006).  
For the current research reported in this dissertation the focus is cancer of the breast or 
mammary glands, a cancer common in women. 
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1.1.2 Breast cancer 
Breast cancer is the leading cause of cancer deaths in women and was reported to account for 
23% cancer cases and 14% cancer deaths in 2008 worldwide (Jemal et al., 2011) . Risks of 
developing cancer have been investigated but no explanation for the international variation in 
frequency and prognosis in breast cancer is known. In South Africa, breast cancer has been 
more common in white women and less common in black and coloured women. Recently, 
however, there has been a tremendous increase in black and coloured women with breast 
cancer. This seems due to several factors including socio-economic factors  and a change to 
westernized diet (Matatiele, 2008).  
Cancer risk factors are almost the same for most cancers. Breast cancer risk factors in females 
include having breast tissues dependent on hormones like oestrogen for growth and a lack of 
child-bearing or child-bearing at an age above 35 years (Cooper, 1993). Longer breast 
feeding has also been claimed to protect women against developing breast cancer (Bray et al., 
2004) .  
Breast cancer has been found to have 5 stages of progression, just like all other cancers. At 
Stage 0, the carcinoma present but no invasion has occurred. At Stage 1, a tumour growth (≤ 
2 cm) is present but there is still no trace of invasion. At Stage II, either angiogenesis has 
occurred but the tumour is still small (≤ 2 cm), or a large tumour (over 5 cm) is present but no 
angiogenesis is evident, or a moderate sized tumour, with or without angiogenesis, is present. 
At Stage III, however, a large tumour with angiogenesis, or tumour of any size with extensive 
angiogenesis, or angiogenesis at the chest wall and skin is present. At Stage IV, the cancer 
has grown beyond the lymph nodes and grown at a distant site from the point of origin (Kols, 
2002). It is the invasive stage that is the most dangerous and forms the target in the current 
study.  
Breast cancers can originate from any tissue of the breast and are named according to 
location of origin or particular features of the disease. Breast cancers more commonly arise in 
the ducts of the breast and are referred to as ductal carcinomas. Fewer arise in the lobules and 
even fewer in other tissues (Cooper, 1993). Invasive ductal carcinomas account for about 
70% of breast cancers and, though they originate inside the ducts, they usually invade into the 
fatty tissues and spread to other parts of the body (Danziger and Simonsen, 2011).  
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Invasive lobular carcinomas begin in the milk glands situated deep inside the breast and 
account for about 10% of the breast cancers. Inflammatory breast cancer is the least common 
kind of breast cancer and is usually found in the soft tissues of the breast, in the form of 
sheets and not in lumps (Stephan, 2009). Medullary carcinoma accounts for the least number 
of breast cancers (about 3-6%) and are more common in woman with a genetic predisposition 
to breast cancer (Danziger and Simonsen, 2011). Paget‟s disease is the rare kind of breast 
cancer and involves the nipple. As invasive cancers are responsible for the highest mortality, 
they remain the target of the current investigation, as treatment of the more advanced, 
refractory cancers remains a problem (Bray et al., 2004) . 
1.1.3 Treatment of breast cancer 
A great deal of research has been focused on finding an improved treatment for cancer. 
Treatment methods that are mainly used are: surgery, radiotherapy, chemotherapy, hormone 
therapy, and antibody-based treatment (National Cancer Institute, 2006; Cooper, 1993). 
Choice of treatment method is based upon the stage of breast cancer progression, i.e. the 
primary tumour, region lymph node involvement, and distant metastasis (Kols, 2002). The 
success of treatment method varies with the type of cancer and how early the tumour was 
detected, more advanced cancers being less easily treated (Cooper, 1993).  
All methods of cancer treatment used alone, or in combination, may vary depending on the 
type of cancer. The primary methods of treatment of early stage breast cancer are surgery and 
radiotherapy. This is because, at early stages, cancers are not invasive and will have not 
metastasized, so they can be completely eradicated by focused treatment or surgical removal 
(Pratt et al., 1994).  
Radiotherapy is usually used post-surgery and involves irradiation (with X-rays or gamma 
rays) of any remaining cancer cells with the aim of destroying the malignant cells. Normal 
cells are also killed, however. For this reason, recent research has focused on finding tumour-
specific antibodies to which radiolabels may be attached to direct radiation specifically to 
tumour targets (Ghosh et al., 2009).  
Another method of treatment is chemotherapy. This involves the treatment of cancer cells 
with anti-cancer drugs. This method is very effective as it can prevent the spreading of cancer 
cells, decrease the size of the tumour and relieve symptoms such as pain (Ghosh et al., 2009). 
To date, by far one of the most effective cancer therapeutics are the anti-angiogenesis drugs. 
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These keep tumours from providing their own blood supply and thereby stopping the supply 
of oxygen and nutrients to the cancerous cells leading them to starve to death (Bluff et al., 
2008). An example is a humanized anti-vascular endothelial growth factor antibody, 
bevacizumab, with the trade name of Avistan. Anti-vascular endothelial growth factor plays a 
critical role in tumour growth and invasion, and Avistan has been known to inhibit the VEGF 
activity and hence control tumour growth (Ranpura, 2011). 
Chemotherapy, on the other hand, is thought to be the most universally effective method of 
treatment, especially for the invasive cancers (Bluff et al., 2008) . This is because this therapy 
can be supplied throughout the blood system. Plant-derived anti-cancer drugs are also 
believed to have great potential as anticancer drugs.  
Anti-cancer chemotherapeutic drugs are classified according to their mode of action. There 
are alkylating agents like cisplatin and mitomycin, DNA cleavage agents like bleomycin, and, 
DNA binders like dactinomycin (Ghosh et al., 2009). Cisplatin is a metal-based anti-cancer 
drug and also an alkylating agent. About 50-70% of cancer patients are treated with platinum-
based drugs. Their strength is illustrated by the fact that hardly any combination 
chemotherapy does not include platinum-based drugs (Hannon, 2007) .  
Natural products have played a critical role in prevention and treatment of diseases for over 
thousands of years (Chin et al., 2006). Egypt, China, India and Greece have been using 
traditional medicines since ancient times and a number of very important drugs have been 
developed from plants (Shoeb, 2006). About 60% of the anticancer drugs are, in one way or 
the other, derived from plants and this suggests that traditionally used plant-derived 
compounds may be a good resource for further drug development. The search for anti-cancer 
drugs derived from plants started in the 1950‟s (Cragg and Newman, 2005; Newman and 
Cragg, 2012).  
The success of the drug can be judged using four criteria, i.e. the rate of introduction of the 
drug onto the market, its potential for laboratory synthesis, the number of diseases treated 
using such a drug, and its level of use in the treatment of specific disease (Chin et al., 2006).  
The first plant-derived anti-cancer drugs to be introduced for clinical use were the Vinca 
alkaloids, vinblastin and vincristine, isolated from Madagascar periwinkle, Catharanthus 
roseus, which belongs to the Apocynaceae family (Shoeb, 2006). Vinblastine and vincristine 
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are primarily used for treatment of a variety of cancers including breast cancer and in 
combination with other chemotherapeutic drugs (Shoeb, 2006) .  
In the 1970‟s camptothecin (CPT) isolated from the Chinese ornamental tree, Camptotheca 
acuminata from Cornaceae family was introduced for clinical trials (Cragg and Newman, 
2003). This plant grows rapidly in areas like China and Tibet, where it is known as the happy 
tree and the camptothecin drug is usually isolated from the bark and stem (Ghosh et al., 
2009). This drug was also used as an anti-cancer drug, but because of severe bladder toxicity 
the use of the drug was discontinued (Shoeb, 2006) . To overcome the side effects of CPT, 
analogues were synthesized e.g. topotecan, exatecan, ironotecan and rubitecan. Exatecan 
derivative is more efficient in killing malignant tumors. It inhibit DNA topoisomerase I 
which plays a major role in various DNA functions like replication and transcription, and has 
a lower toxicity against normal cells (Nirmala et al., 2011).  
Paclitaxel, trade name Taxol®, is isolated from the Pacific Yew, Taxus brevifolia of the 
Taxaceae family and has been reported for it‟s anti-tumour activity against rodent tumours 
(Ghosh et al., 2009). Paclitaxel with other precursors actually occur in a number of Taxus 
species e.g. T. canadensis, T. baccata, T. cuspidate and T. mairei lemee (Cragg and Newman, 
2003). Initially paclitaxel was only sourced from the Pacific Yew, but recently this has been 
made semi-synthetically (Ghosh et al., 2009).  
Paclitaxel has been reported to be significantly active against ovarian cancer, advanced breast 
cancer and lung cancer (Shoeb, 2006) . However, it is poorly water-soluble and toxic, and, 
this led to the preparation of a semi-synthetic derivative, docetaxel which was found to be 
more effective. Both drugs are still in use as first and second line treatments. If the malignant 
tumour is resistant to paclitaxel, docetaxel is normally used in cases of breast cancer and 
ovarian cancer (Nirmala et al., 2011).  
Podophyllotoxinis is a clinically used anticancer drug extracted from the roots of 
Podophyllum species i.e. peltatum and emodi. Epipodophyllotoxin is the podophyllotoxin 
isomer that has two semi-synthetic derivatives, i.e. etoposide and teniposide and their 
application has been reported in a number of cancer treatment regimens such as in 
lymphomas and bronchial and testicular cancers (Shoeb, 2006) .  
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Ellipticine is also a plant-derived anti-cancer drug isolated from a Bleekeria vitensis found on 
a Fijian island. This drug was derivatized to produce elliptinium which is now well known in 
France for treatment of breast cancer (Shoeb, 2006) . 
The above-mentioned, plant-derived anti-cancer products are already in clinical use for 
cancer treatment. In 2002, paclitaxel and camptothecin were the most used compounds and 
were estimated to account for one-third of the worldwide anti-cancer drugs supplied to the 
market (Shoeb, 2006) . There are still a number of natural anti-cancer products in clinical 
trials (Albrecht et al., 1995a). Few clinical trials have been carried out on the compound used 
in the current study i.e. hypoxoside, isolated from Hypoxis hemerocallidea. Natural products 
were used as traditional medicine in bygone times, and to this day traditional healers make 
use of them. For this reason, derivatives of a constituent of a locally-available traditional 
medicinal plant, Hypoxis hemerocallidea, were prepared and investigated for anti-cancer 
properties in this study. 
1.2 TRADITIONAL MEDICINE 
Traditional medicine is currently being used by about 80% of the developing world and there 
are as many as 100 000 traditional healers in South Africa alone (Owira and Ojewole, 2009) . 
South Africa is one of the richest centers in plant diversity in the world and that contributes to 
the high numbers of traditional healers who mainly use medicinal plants (Mulholland and 
Drewes, 2004). Traditional medicines go back a long time in history, especially in Africa. For 
treatment of many kinds of diseases and recently even for treatment of HIV/AIDS (Mills et 
al., 2005). The interest in traditional medicines has increased recently and has drawn the 
attention of not only the government and research laboratories, but also pharmaceutical 
companies, in order to use the scientific knowledge and therapeutic properties of African 
traditional medicines (Owira and Ojewole, 2009) . 
1.2.1 Hypoxis hemerocallidea 
One of the most important traditional plants that has always been popular and is still largely 
used is Hypoxis hemerocallidea Fish. Mey. & Ave-Lall (Hypoxidaceae), previously known as 
H. rooperi. There are at least 100 other different Hypoxis species and at least 3 are used in 
traditional medicine, i.e. Hypoxis colchicifolia Baker, Hypoxis gerrardii Baker and H. 
hemerocallidea, (Hutchings et al., 1996). It has a tuberous root (corm) which is commonly 
known as the African potato (AP) (inkomfe or ilabatheka in isiZulu) and can be easily 
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recognized by its bright yellow flowers and strap green leaves (Drewes et al., 2008; Nair et 
al., 2007) (Figure 2.1).  
The AP extracts have been used as traditional medicine in treatment of many diseases like 
tuberculosis, common cold, flu, hypertension, diabetes mellitus, psoriasis, urinary infections, 
testicular tumours, prostate hypertrophy, internal cancer, cardiac diseases,  HIV/AIDS and 
some central nervous disorders (Drewes et al., 2008; Laporta et al., 2007a; Zibula and 
Ojewole, 2000). The main component of the AP extract is a norlignan diglucoside, 
hypoxoside, which is a trivial name for (E)-1,5-bis(4‟-β-D-glucopyranosyloxy-3-
hydroxyphenyl)pent-4-en-1-yne, a pale yellow water soluble crystalline compound that is 
readily converted into a lipophilic aglucone, rooperol, in the presence of β-glucosidase 
(Figure 1.2). The pentenyne system connecting the two aromatic rings is rare in nature. It is 
significant that, with this arrangement the central CH2 group, the compound becomes 
prochiral, an important stereochemical attribute for biological activity (Drewes and Khan, 
























Figure 1.2: Conversion of hypoxoside into rooperol. 
The hypoxoside molecule contains two β-glucose moieties. When the enzyme β-glucosidase 
reacts with hypoxoside, the two glucoside bonds are hydrolysed, the resultant compound, 
named rooperol, has exposed hydroxyl groups instead of glucosyloxy substituents and has 
very different properties to its parental structure (adapted from Albrecht et al., 1995b). 
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Hypoxoside was initially isolated with a methanol/butanol extraction procedure and its 
structure was elucidated using NMR and UV spectroscopy (Bettolo et al., 1982). Extraction 
with ethanol, however, gave a better percentage yield and was hence used in the current 
study. Hypoxoside is pharmacologically inactive but is transformed into its biologically 
active form rooperol, in the large intestines or by the liver cells of humans, by the enzyme β-
glucosidase (Drewes et al., 1984; Kruger et al., 1994). In vitro hypoxoside is non-toxic to 
normal cells but becomes toxic to cancer cells as they produce the enzyme β-glucosidase that 
converts the hypoxoside into active rooperol (Albrecht et al., 1995a). 
1.2.2 Uses of Hypoxis hemerocallidea 
Many scientific reports have reported that the AP extract is a possible remedy for a variety of 
pathophysiological disorders. Zibula and Ojewole (2000) reported that the methanol extract 
from the African potato induces hypoglycemic effects in both normal and hyperglycemic rats 
(Zibula and Ojewole, 2000). The anti-oxidative activity of prepared aqueous AP was found to 
be significantly higher than that of extracted hypoxoside, but lower than that of rooperol. This 
anti-oxidative activity is due to the dicatechol-like structure which hypoxoside assumes when 
converted to rooperol (Figure 1.3). It behaves in a similar fashion to the known antioxidant, 
nordihydroguaiaretic acid (Bettolo et al., 1982; Drewes et al., 1984; Nair et al., 2007).  
Cell membranes are lipophilic and since rooperol is more lipophilic than hypoxoside, this will 
allow rooperol to penetrate cells more readily than hypoxoside. Rooperol was found to have 
strong anti-microbial activity and was able to inhibit cycloxygenase-1 (COX-1) and 
cycloxygenase-2 (COX-2) which contributes to the anti-inflammatory and anti-noceptive 
activity of this compound (Laporta et al., 2007a; Ojewole, 2006). Childhood convulsions and 
epilepsy may result in death, especially in rural areas, but treatment with AP has been shown 
to improve this ailment (Ojewole, 2008). The main focus of the current study was to test 
hypoxoside and two derivatives as anti-cancer pro-drugs and this activity was assessed on 
two different adherent cell lines i.e. a normal MCF10A and its premalignant derivative 










































Figure 1.3: Rooperol acting as an anti-oxidant. 
Rooperol acts like any anti-oxidant and has the required features of a good anti-oxidant, i.e. a 
benzene ring with 1,2-hydroxy or 1,4-dihydroxy groups. The function of anti-oxidants is to 
scavenge free radicals. The hydroxyl group interacts with the free radical and, ultimately, an 
ortho-quinone forms. In the process free radicals are destroyed (Drewes and Khan, 2004) . 
1.3 DRUGS EFFECTIVENESS 
For a drug to be deemed effective, it must have a selective effect on the target cell. In this 
case this should be on the specific cancer type, either depressing cancer cell growth or 
metabolism. If it is selectively toxic to cancer cells and not normal cells, then it should induce 
cell death by apoptosis and not necrosis, as the latter may be life-threatening (Cooper, 1993). 
Apoptotic death may be induced by a variety of stimuli and via specific receptors. Not all cell 
types will die after treatment with the same compound, or at the same concentration. The 
latter too may determine whether the cell will die through apoptosis or necrosis and this is 
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important to assess as induction by necrosis may have life-threatening consequences (Bertho 
et al., 2000; Pereira and Amarante-Mendes, 2011).  
1.3.1 Cell death 
Since the major aim of most therapeutic interventions is to induce apoptosis and not necrosis, 
the mechanisms of inducing either form of cell death are briefly described. Detection 
methods which may be used to assess which mode of cell death is induced will be described. 
 
Figure 1.4: Differences between apoptosis and necrosis. 
Apoptosis involves chromatin and nucleus condensation, blebbing of the plasma membrane, 
formation of apoptotic bodies and finally their engulfment and further digestion. Necrosis 
involves swelling of the necrotic cell, loss of plasma-membrane integrity and finally bursting 
of the cell, resulting in the release of the cytoplasm content and DNA to the surrounding cells 
causing inflammation. Caspase-activated DNAse (CAD) DNAse I and DNAse II are the main 
nucleases involved, as indicated in bold. HMW cleavage = higher molecular weight cleavage 
of DNA, LMW cleavage = lower molecular weights cleavage of DNA (also called DNA 
ladders), topo II = topoisomerase II, endo G = endonuclease G. DNAse I and II are referred to 
as waste management nucleases (Samejima and Earnshaw, 2005).  
There are two major mechanisms of cell death that cells can employ when they are stressed or 
damaged, programmed cell death (apoptosis) or non-programmed cell death (lysis or 
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necrosis) (Figure 1:4). Apoptosis and necrosis can be distinguished according to their 
biochemical and morphological features (Leist and Nicotera, 1997). Whether the cell will die 
through apoptosis or necrosis depends on the intensity of the attacking onslaught. Some 
studies reported that ATP concentration influences the chosen type of cell death (Fadeel and 
Orrenius, 2005).  
Apoptosis, is referred to as programmed cell death (PCD), has been widely recognized by 
diverse fields of scientific research (Darzynkiewicz et al., 1992; Darzynkiewicz et al., 1997). 
It was initially discovered by Carl Vogt in 1842 during an amphibian development study, and 
was called Programmed Cell Death (PCD). The term apoptosis which was suggested by 
James Cormack, a professor of Greek language, refers to the dropping off of leaves from a 
tree (Kerry et al., 1972; Pereira and Amarante-Mendes, 2011). 
Recently it has been discovered that there are actually three kinds of PCD patterns, i.e. 
apoptosis, autophagy and necroptosis (Peter, 2011). Apoptosis refers to the well-recognized 
type of cell death that is caspase-dependent, that has associated morphological changes that 
includes nuclear and cytoplasmic condensation, blebbing of the plasma membrane that 
eventually results in the cell breaking up into a membrane-enclosed apoptotic bodies (Fadeel 
and Orrenius, 2005). Autophagic cell death is regulated by the availability of nutrients for the 
cells but under limited nutrients the cell will digest itself until death (Peter, 2011). 
Necroptosis is a recently found kind of necrosis that shows sequential regulation by the 
kinase receptor interacting proteins (RIKP) family which shows some “cross talking” with 
apoptosis and is activated if the extrinsic apoptotic pathway is activated while apoptosis is 
inhibited (Declercq et al., 2009).  
Morphological features of necroptosis are the same as that of necrosis but its inducing 
stimulus and programmed nature is like that of apoptosis (Wang et al., 2007) . In necroptosis 
studies, a specific small molecule inhibitor of necroptosis, necrostatin-1 has been identified. 
This provides an opportunity to evaluate significant functions of necroptosis although the 
mechanism is still not well understood (Li et al., 2008). 
Since apoptosis is a normal, physiologically active, and not accidental, with a clearly 
understood mechanism of induction, scientist have recognized that most, if not all, 
physiological cell death occurs through apoptosis (Fadeel and Orrenius, 2005). Apoptosis 
does not cause an inflammatory response as it does not release it‟s cellular content to the 
surrounding and it is tightly regulated and maintains homeostasis perfectly (Gavrilescu and 
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Denkers, 2003). Therefore, for chemotherapy, induction of apoptosis, rather than necrosis of 
diseased cells, is a desired outcome (Rastogi et al., 2009).  Selectively triggering apoptosis as 
a form of cell death in a premalignant cell line and not the normal cell line is, therefore, an 
aim in the current study. 
1.3.2 Apoptosis 
Apoptosis is a physiologically active process of cell death in which the cell itself devises a 
program for death and homeostasis (Bertho et al., 2000; Darzynkiewicz et al., 1997). The 
PCD process appears to play an important role in living organisms. In cellular development 
and aging it acts as a homeostasis mechanism for maintenance of cellular populations and 
acts as a defense mechanism, through the immune response, and induction of natural death of 
infected cells (Bertho et al., 2000; Elmore, 2007).  
Tumour growth is usually associated with loss of apoptotic regulation and radiotherapy and 
chemotherapy are designed to result in apoptotic tumour cell death. Compounds that can 
induce apoptotic tumour cell death are very important in cancer chemotherapy (Zamai et al., 
2001). Apoptosis can be initiated to work through two distinct apoptotic pathways, i.e. 
intrinsic and extrinsic as well as perforin/granzyme pathway (Figure 1.5). All these apoptotic 
pathways give rise to biochemically distinguishable initial events (e.g. they activate different 
caspases) and finally result in a common executioner pathway (Elmore, 2007) in which 
cytomorphic and other changes such as changes in membrane component distribution (Figure 
1.4). The most important pathway relevant to induction of apoptosis in target cells is the 




Figure 1.5: Different programmed cell death pathways. 
All the apoptotic pathways result in the activation of the execution pathway. When the 
execution pathway is activated, a cascade of apoptotic events occur which all give rise to 
visible changes in the cell‟s physical appearance. The only mechanism relevant to drug-
induced cell death is the intrinsic pathway. MTP = mitochondrial changes, SET complex = 
270–420 kDa protein complex (adapted from Elmore, 2007). 
1.3.2.1 Intrinsic apoptotic pathway  
The intrinsic pathway of inducing apoptosis is a mitochondrion-dependent apoptotic pathway 
which usually responds to the extracellular signals and internal insults such as DNA damage, 
toxins, radiation, hypoxia, hyperthermia, viral infection and free radicals (Elmore, 2007) and 
is important in drug-induced cell death. This pathway is mainly regulated by members of the 
Bcl-2 family of proteins, found in mitochondria. These share one or more Bcl-2 homology 
(BH) domains. There are anti-apoptotic members (A1, Bcl-2, Bcl-XL, MCL-1 and Bcl-W) 
with all four BH domains and pro-apoptotic members (BAX, BAK and BOK) with no BH4 
domain.  
There is another subset of special pro-apoptotic proteins. These display only the BH3 domain 
(BID, BIM, BAD, BIK, BMF, NOXA and PUMA) responsible for inter-molecular 
dimerization amongst the members, a process essential for their pro-apoptotic function. These 
proteins are referred to as “BH3 only proteins” and are capable of binding each other in an 




Figure 1.6: Mechanism of the intrinsic apoptotic pathway.  
In response to DNA damage through chemotherapeutic drugs or ultraviolet radiation, the p53 
gene is activated. This activates the expression of the BH3 only members, BIM and BMF. 
Growth factor withdrawals lead to the down regulation of the Akt pathway and, therefore, 
dephosphorylation of BAD and release from the 14-3-3 chaperon. When all the BH3 only 
members are activated they induce the BAX/BAK channel, leading to MOMP. This leads to 
the executioner pathway. Bcl-2 = B cell lymphoma 2, BH3 = Bcl-2 Homology domain 3, 
BAD = Bcl-2-associated death promoter, BAX = Bcl-2–associated X protein, MOMP = 
mitochondrial outer membrane permeability, BAK = bcl-2 homologous antagonist/killer, GRF 
= growth receptor factor (Pereira and Amarante-Mendes, 2011). 
In response to the cell internal insult, the p53 is activated by the cascade of proapoptotic 
proteins and induces the over expression of regulatory pro-apoptotic proteins (i.e. NOXA and 
PUMA) (Figure 1.6). These proteins activate the over expression of the BH3 only proteins, 
BAX and BAK. The withdrawal of growth factors occurs and, therefore, the 
dephosphorylation of the BH3 only member, BAD, BAD subsequently is released from a 
cytoplasmic 14-3-3 chaperone. This directs BAD to the mitochondria. The cell internal 
stresses interfere with the cell‟s cytoskeleton dynamics and induce activation of the BH3 only 
protein members, BIM and BMF. This in turn induces mitochondrion-mediated apoptosis 
(Elmore, 2007; Rastogi et al., 2009) (Figure 1.6). 
A BAX and BAK channel is formed through the activation of the BH3 only proteins. This 
induces mitochondrial outer membrane permeability (MOMP) and, therefore, cytochome c 
release. The mitochondrial cytochrome c binds to apoptotic protease activating factor 1 
(APAF-1) and procaspase-9, activating the formation of the apoptosome complex (Figure 
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1.6). The clustering of procaspase-9 in such a complex results in its activation to caspase-9 
which cleaves and activates the common executioner caspases, and subsequently the cell is 
committed to apoptosis (Schuler and Green, 2001) (Figure 1.6). 
1.3.2.2 Extrinsic pathway 
The extrinsic pathway is less likely to be involved in drug-induction of cell death as it is a 
receptor-mediated pathway mainly responsible for maintenance of tissue homeostasis(Fadeel 
and Orrenius, 2005) (Figure 1.7). This pathway is p53-tumour suppressor gene-dependent 
since the production of the trans-membrane receptor protein (i.e. Fas, DR5 and PERP) is 
dependent on the level of p53 expressed. This determines the level at which genes coding for 
the apoptotic trans-membrane proteins (Figure 1.7). These extrinsic pathway death receptors 
(DR) are characterized by their content of an 80 amino acids long domain referred to as death 
domain (DD) (Jonnalagadda et al., 2008). This determines the specificity of the ligand for its 
receptor (Pereira and Amarante-Mendes, 2011). All the death receptors in this pathway 
belong to the tumour necrosis factor receptor (TNF-R) family. The T-cell secreted death-
inducing protein FasL activates Fas. DR5, activated by binding to the TNF-related apoptosis 
inducing ligand (TRAIL), and the p53 apoptosis effector related to PMP-22 (PERP), 
cooperate to induce apoptosis by an, as yet, unknown mechanism (Haupt et al., 2003). 
Ligation of the death receptor, e.g. the FasL binding to the receptor Fas, induces the 
formation of a death-inducing signaling complex (DISC) which in turn recruits procaspase-8 
(Figure 1.7). When the procaspase-8 levels increase, procaspase-8 is automatically activated 
to caspase-8. This sequentially activates the executioner caspases (3, 6 and 7) (Elmore, 2007). 
The cell will subsequently be directed to Type I extrinsic apoptosis or caspase-8 can process 
the BH3 only member BID to a shortened BID (tBID) which will be transported to the 
mitochondrion and induces mitochondrial outer membrane permeability (MOMP). This 
results in the release of cytochrome c into the cytoplasm. This sequentially induces the 
formation of the apoptosome (APAF-1/procaspase-9) complex and the activation of the 
executioner caspases. This subsequently results in mitochondrion-dependent apoptosis (Type 
II) (Haupt et al., 2003; Pereira and Amarante-Mendes, 2011) (Figure 1.7). The alternative 












Figure 1.7: Extrinsic apoptotic pathway mechanism.  
Clustering of the Fas L and Fas death receptors and induce the adaptor protein FADD and 
procaspase-8 can cleave the executioner pathway proteins or cleaves Bid into a truncated form. 
This is released to the mitochondrion and induces MOMP. Therefore, the release of 
cytochrome c is induced and the APAF-1/caspase-9 apoptosome is formed. This induces the 
executioner pathway. PERP = p53 apoptosis effector related to PMP-22, Apaf-1 = apoptosis 
protease-activating factor-1 (adapted from Pereira & Amarante-Mendes, 2011). 
1.3.2.3 Perforin/granzyme apoptotic pathway 
T-lymphocytes and natural killer cells use a perforin/granzyme pathway to target and destroy 
infected cells. If the lymphocyte detects some kind of abnormality in the cell, it will trigger 
apoptosis and either the FasL/FasR interaction or perforin/granzyme-dependent pathway 
(Fadeel and Orrenius, 2005). The perforin/granzyme pathway is the main mechanism used by 
the cytotoxic T lymphocytes, and, therefore, not important for drug discovery since, as 
mentioned before, toxins/drugs activate the intrinsic apoptotic pathway.  
What happens in this pathway is that the lymphocytes secrete perforin and granzyme via 
granule exocytosis upon detection of any abnormality within any cell. Perforin is a 
membrane-disrupting protein that is capable of forming a pore in the surface of the cell 
membrane and granzymes are serine proteases. These proteins work together to induce 
apoptosis. Granzymes trigger apoptosis in the target cell and perforin delivers them 
appropriately into the target cell (Trapani and Smyth, 2002). 
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There are two kinds of granzymes, i.e. granzyme A and granzyme B. Granzyme B can cleave 
proteases at aspartate residues and will cleave caspase-10 (the initiator caspase). This will 
subsequently activate the executioner caspases. Granzyme B has been reported to cleave Bid 
(BH3 interacting domain death agonist) and, therefore, result in the induction of the 
mitochondrial-dependent death pathway. Again this protease can also directly activate 
caspase-3, inducing the execution phase of apoptosis (Elmore, 2007). Granzyme A drives 
apoptosis in a caspase-independent pathway where it cleaves the SET complex and thereby 
activates the DNAse (NM23-H1) which will activates DNA degradation, thereby contributing 
to apoptosis (Calaf et al., 1995). Apoptosis induced via the extrinsic, intrinsic and 
perforin/granzyme pathways can be distinguished biochemically by detection of caspase-8 
(extrinsic), caspase-10 (perforin/granzyme) and caspase- 9 (intrinsic) in early stages of 
apoptotic cell death. All these pathways at late stages of apoptosis give rise to the common 
caspase-dependent executioner pathway.  
1.3.3 What do the common executioner caspases do? 
In extrinsic, intrinsic and perforin/granzyme pathways the end point is the execution phase. 
This is considered the final stage of apoptosis. The execution phase is actually carried out by 
specific proteolytic enzymes such as caspase-3, caspase-6 and caspase-7. These are 
responsible for the actual physical effects seen late in apoptosis (Vaskivuo, 2002). All these 




Figure 1.8: Executioner caspases and their substrate recognition for induction of 
     apoptosis. 
The common executioner pathway results in cell shrinkage, membrane blebbing, DNA 
fragmentation and inhibition of DNA repair genes. CAD = caspase-activated 
deoxyribonuclease; FADD = Fas-associated death domain; ICAD = inhibitor of caspase-
activated deoxyribonuclease; PARP = poly (ADP-ribose) polymerase; TRADD = tumour 
necrosis factor receptor-associated death domain (adapted from Fan et al., 2005). 
Caspase-3 is recognized as the main enzyme in the execution phase and is activated by any of 
the initiator caspases (caspase-8, caspase-9 and caspase-10). This caspase cleaves the 
inhibitor caspase activated DNAse (ICAD) and subsequently releases caspase-activated 
DNAse (CAD). CAD is an endonuclease responsible for degradation of chromosomal DNA, 
and, therefore, causes chromatin condensation. It activates cytoskeleton disruption and the 
budding off into apoptotic bodies through cleavage of gelsolin, an actin-binding protein 
(Elmore, 2007). 
Cleavage of lamin A and fodrin by caspases (as indicated in Figure 1.8) results in chromatins 
condensation and decomposition of nucleus and formation of apoptotic bodies. Poly ADP-
ribose polymerase (PARP), DNA-dependent protein kinases (DNA-PK) and steroid response 
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element binding protein (U1,70 KD) are the proteins involved in DNA repair, so once they 
are cleaved by caspases they become inactivated and, therefore, DNA degradation results 
(Fan et al., 2005). Eventually, when all caspases are activated, a cell will undergo many 
physical changes and die (Figure 1.8). 
1.3.4 Regulators of apoptotic cell death 
In all apoptotic pathways caspases are a very important family of proteases referred to as 
aspartate-specific cystein proteases that mediate apoptosis. They are single chain proteins 
with an amino terminus pro-domain, large subunit in the middle with an active site and the 
carboxy terminal small subunit. To date about 14 caspases have been discovered and not all 
of them play a role in apoptosis. Caspases are regulated at post-translational level to ensure 
that they are regularly activated (Cohen, 1997; Pereira and Amarante-Mendes, 2011). There 
are inflammatory caspases (which includes caspases-1, -4, -5, -11, -12 and -13) and all the 
others are involved in apoptosis. The apoptosis-inducing caspases are divided into two 
groups. There are initiator caspases (-2, -8, -9 and -10) which are activated through 
dimerization through the effect of multimeric complexes like the apoptosome and death-
inducing signal complex (DISC), and executioner caspases (-3, -6 and -7) already expressed 
as dimers and activated by cleavage of the pro-domain from the large and small subunit 
(Cohen, 1997; Fadeel and Orrenius, 2005; Nicholson, 1999; Pereira and Amarante-Mendes, 
2011).  
Another mediator of apoptosis is the p53 tumour suppressor gene or transcription factor that 
induces cell death to restrict irregular cellular growth. This gene restricts cellular growth 
through apoptosis.  
1.3.5 Methods of assessing cell death (apoptosis or necrosis) 
Apoptosis is not only a process for cell homeostasis but removes infected or damaged cells 
from the system (Martinez et al., 2010). In chemotherapeutic testing of drugs, selective 
cytotoxicity is of importance and provides preliminary data for in vivo studies i.e. evidence 
that test drugs can induce apoptotic cell death in vitro in tumour cell lines, but do not affect a 
normal cell line (Zamai et al., 2001).  
Methods for evaluation of cell viability are mostly dependent on proliferation and metabolic 
activity. Other methods developed include those based on direct cell counting, differential 
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staining and DNA integrity (Wang et al., 2010). Each checks a different, differential effect 
and all have some merit for the determination of the effect of a test compound, though each 
has its own weakness.  
As the morphological characteristics of dead or dying cells include the loss of cell membrane 
integrity, many assays for cell viability depend on this characteristic. When fluorochromes 
like PI, ethidium bromide (EB),7-amino-actinomycin D (7-AAD) and trypan blue (TB) are 
incubated with live and dead cells, the dyes will be excluded by the live cells with intact cell 
membrane, but stain the late apoptotic and necrotic cells showing loss of cell membrane 
integrity (Darzynkiewicz et al., 1997).  
Acridine orange (AO) and Hoechst (HO) are fluorochromes that are different from such dyes 
as they stain even the live cells with intact membranes. Use of one of these membrane-
permeable stains, with one of the already mentioned non-cell-permeable dyes (in intact cells), 
allows one to distinguish between late apoptotic and necrotic cell death (stain green with AO 
and also red with PI, respectively), and early apoptotic and live cells (staining green with AO 
and without staining for PI) and is cheap and easy to use (Bradbury et al., 2000). Whether 
necrosis and late apoptosis are distinguished, however, is unclear as staining intensity of 
propidium iodide has been reported to simultaneously detect living (PI-negative), apoptotic 
(PI-weak cytoplasmic staining) and necrotic (PI-bright staining) cells, when unfixed cells are 
exposed to supravital staining (Zamai et al., 2001). The latter study contradicts the study by 
Bradbury et al. (2000), in that intensity of PI staining is used to distinguish apoptosis from 
necrosis whereas lack of PI staining is taken to indicate early apoptosis and PI staining to 
indicate necrosis in the results of Bradbury et al. (2000). PI, nevertheless, seems to represent 
one of the most important dyes for detection of cell death (Bradbury et al., 2000).  
Cell membrane disruption, during various insults, causing expression of thrombospondin 
binding sites, loss of sialic acid residues and exposure of phosphatidylserine (PS) by 
apoptotic cells, allows the development of cell viability detection methods. PS is a 
phospholipid normally present in the plasma membrane, facing the cytoplasm. During early 
apoptosis, the plasma membrane asymmetry is disrupted and the PS is exposed on the cell 
surface.  
Annexin V is an expensive protein that binds phospholipids like PS, if exposed on the surface 
of a cell dying via apoptosis. Dye-labeled annexin V allows the detection of such surface-
exposed PS. In early apoptotic cells, annexin V staining is positive and no staining for PI is 
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seen. Alternatively, staining with both detection systems can occur in late apoptosis and 
necrosis. Unfortunately, the two different types of cell death cannot be distinguished by this 
method (Verms et al., 1995). It has been reported that annexin V staining is only suitable for 
apoptosis detection in cells occurring naturally in a suspension. Unfortunately, during 
application in studies on adherent cells, PS exposure may either occur as an artifact due to 
membrane damage caused by treatments used to dislodge cells. This may give rise to false 
annexin V binding and false positive results (Van England et al., 1996). This limits the use of 
such a technique for adherent cells. 
Caspase assays are similarly expensive and time consuming, though assays for caspase-8, -3 
and -9, and caspase-10 may be used to detect induction of cell death via the extrinsic, 
intrinsic and perforin/granzyme pathways (Figure 1.5). For the current study, a high-
throughput, simple, minimally expensive method was sought, and imaging and flow 
cytometry using an inexpensive dye was considered. 
Imaging (microscopy), flow cytometry and transmission electron microscopy (TEM), at low 
and higher magnification may assist the simultaneous viewing and result assessment of a 
large number of cells (Krysko et al., 2008). Finally it was thought that light and fluorescence 
microscopy may be best used if cost and time is a consideration. 
When using simple light microscopy and performing cell counts using a hemocytometer, a 
popular dye to use for detection of dead cells is trypan blue (Coder, 1997). This constitutes a 
simple and cheap, but less time-consuming method for cell death assessment, trypan blue 
labelling cells with permeable membranes i.e. dying, late apoptotic or necrotic cells . For 
fluorescence microscopy, double staining with AO (green) and ethidium bromide (EB) 
(purple) or PI (red) is often used to similarly establish the percentage of viable (stained 
green), early apoptotic (stained green) as well, late apoptotic or necrotic cells (nuclei both 
stained red), like use of annexin V and PI systems, with similar results, though it seems that 
such dyes may not easily differentiate between apoptotic and necrotic cells (Baskić et al., 
2006), it seemed worthy of investigation. 
Cell counts may be used to monitor both stimulation and depression of proliferation and 
indirectly the induction of cell death. Another way of indirectly assessing the effect of test 
compounds is using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) (MTS) assay, a calorimetric method of estimating cell viability 
using assessment of metabolic activity. Here the metabolic rate of cells is a measurement as 
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metabolism is largely proportional to the number of viable cells (Bunger et al., 2002). This 
method, however, is not reliable for use on its own as metabolic activity is not only 
proportional to the cell number, but the effect of a compound on the metabolism of the cells. 
Cells show depressed metabolic activity after treatment may also show no decreased cell 
numbers, or cell death, as decreased metabolic rate does not necessarily mean the cells are 
dying (Wang et al., 2010).  
Assays for metabolic activity check cytotoxic effects but are also highly depended on cell 
number. Cell numbers should, therefore, be checked, before and after treatment, to allow 
interpretation of results.  
Imaging techniques, using dyes that indicate cell death are used to distinguish apoptosis from 
necrosis on slides seeded with adherent cells. These may not give an accurate reflection of the 
numbers of dead cell as cells may detach before dying. Flow cytometry, using the same such 
dyes, may detect those cells that have detached if cell supernatants are included in the assay. 
Though there are many ways to assess apoptosis, all have their weaknesses, as does the 
propidium iodide (PI) staining method used in this study. For this reason a number of 
methods should be employed to confirm results. 
Flow cytometry is popular for the rapid analysis of a large group of individual cells (Bertho et 
al., 2000). The morphological properties associated with cell death can be easily revealed by 
flow cytometry using the side scatter and forward scatter mode (see Section 3.2.6.1). Physical 
parameters such as DNA content, expression of antigens such as annexin V and membrane 
integrity can be assessed using the side scatter (for morphology) or forward scatter (for 
fluorescence) mode of analysis. This method has been proven to be very useful as it is rapid 
and may be used to assess a number of parameters (Telford et al., 2004), but also compensate 
for cells not imaged using fluorescence microscopy, due to detachment before or during cell 
death. Flow cytometry, therefore, seemed an attractive option for the current study. 
Assessment of DNA integrity, using methods such as DNA laddering, single cell gel 
electrophoresis (SCGE) (or Comet) assay, terminal dUTP nick end-labeling (TUNEL) and 
nick translation assays may also be used, but are technically challenging, time consuming and 
expensive. DNA laddering involves isolation and assessment of DNA using gel 
electrophoresis. Fragmentation of the DNA only becomes significant when a large proportion 
of the population of cells is apoptotic and DNA is easily sheered during DNA preparation 
giving false positive results indicating necrosis (smearing of bands). Therefore, this method 
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should generally not be used alone to draw conclusions (Abdullah et al., 2010) . The presence 
of DNA fragments in a cell can also be confirmed by TUNEL assay. 
The TUNEL assay involves detection of the fragmented DNA in individual apoptotic cells. 
The terminal deoxynucleotidyl transferase adds the dUTP to the 3‟-OH end of the fragmented 
DNA. dUTP can be subsequently labeled with a variety of probes to permit detection with 
light microscopy, fluorescence microscopy and flow cytometry (Elmore, 2007). This 
technique is very sensitive and fast but very expensive. How many DNA breaks are needed 
for detection to occur is unknown. Therefore, another method of confirming results is 
required (Tumburrino et al., 2011).  
The Comet assay, where electrophoresis is performed on whole permeabilized cells, allows 
the visualization of a comet tail, indicating the DNA cleavage associated with either 
apoptosis or necrosis. This method is known for being very sensitive but technically difficult 
to perform and difficult to interpret (Yasuhara et al., 2003) and, therefore, was not considered 
for the current study. 
Cell counts, the MTS assay, supravital staining and imaging of PI and AO-treated cells on 
glass slides, and PI staining and flow cytometry (PI being used rather than annexin V as test 
cell lines to be used were adherent) were simultaneously assessed. Each compound was 
assessed on a model system of a normal MCF-10A breast epithelial cell line and its c-Ha ras 
transfected, premalignant, invasive derivative, to assess any differential effect of the parental 
HYP and its two derivatives.  
1.4 MCF10A  
The Michigan Cancer Foundation (MCF) developed a series of human mammary epithelial 
cell lines from a 36 year woman with fibrocystic disease (Miller et al., 1993). The breast 
tissue from a 36 year old, premenopausal woman, with no family history of breast cancer was 
used. Histological examination of breast tissue revealed no malignancies, but extensive 
fibrocystic disease, characterized by an increase in fibrous tissue and a number of dilated 
mammary ducts, an abnormal increase in growth of ductal cells, with no evidence of 
abnormality (Soule et al., 1990). 
The immortal MCF10 cell line was isolated and characterized and found to spontaneously 
immortalize in culture. The mortal MCF10M cells were found to senesce when cultured in a 
media containing normal calcium concentrations (1.05 mM) but gave rise to an immortal cell 
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line that grows either as an attached cell, in normal calcium concentrations (MCF10A) or as a 
free floating cell line (MCF10F) in medium containing 0.04 mM calcium (Tait et al., 1990). 
The MCF10A cells are frequently used as a normal control in breast cancer studies since they 
show the morphological characteristic of normal breast epithelial cells (Zientek-Targosz et 
al., 2008). These cells do not express any mutations in the p53 gene but show homozygous 
loss of the p16/p15 locus making them immortal, i.e. a phenotype similar to one in which p53 
is mutated. They do not form tumours in mice or colonies in soft agar, but, at confluence, 
these cells do not form dome structures in tissue culture but form mammary spheres at 3D 
collagen culture (Zientek-Targosz et al., 2008). The MCF10A cells have several advantages 
over other currently available cell lines because they are not treated with pro-carcinogens, the 
cells do not harbour SV40 genetic information, but are cells with normal polarized 
characteristics like normal breast epithelial cells, i.e. show a typical apical and basal domain, 
and their karyotype is near diploid with minimal rearrangements (Calaf et al., 1995). If an 
oncogene‟s role in tumour progression is to be studied, introduction of such an oncogene into 
such a normal control allows the oncogene to be studied relative to a normal cell of the same 
genetic background, easily revealing the effect of the oncogene. 
1.4.2 MCF10A transformation 
More than 50% of breast cancers exhibit increased levels of activated Ras (Basolo et al., 
1991) and so to evaluate the selective effect of a compound on a cell line with increased 
levels of active Ras, a mutated (VAL-12) Harvey ras gene was introduced into a suitable 
acceptor cell, the MCF-10A cell line (Calaf et al., 1995). This parental cell line was 
transformed to a premalignant cell line using transfection using the Homer 6 (Ph 06) plasmid, 
containing the neomycin-resistance gene for clone selection of transformed cells. The 
construct inserted into the plasmid contained the human T24 H-ras mutation or Val-12 
mutated c-Ha-ras oncogene first isolated from a bladder cancer. Cells transformed with such 
a construct were subsequently called the MCF10A-NeoT cell line (Basolo et al., 1991). 
Transformed MCF10A cells acquired a malignant phenotype, i.e. show clumping in high 
confluent cultures, 3-dimensional growths in collagen, show anchorage independence and are 
invasive (Russo et al., 1991). 
A combination of these two test cell lines, representing the normal and a premalignant 
invasive phenotype, represent a unique test system in which to explore the selective toxicity 
of a drug specifically aimed at H-Ras-related breast cancer malignancies. 
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1.5 RESEARCH AIMS AND OBJECTIVES 
The aim of the current study was, therefore, to: 
 Isolate and purify hypoxoside from the Hypoxis hemerocallidea, through 
extraction of its corms with ethanol and further isolation with pre-packed reverse-
phase column. 
 Prepare two derivatives from pure hypoxoside through methylation and 
acetylation, resulting in a dimethyl and a decaacetyl derivative, respectively.  
 Confirm the purity of hypoxoside and the derivatives using NMR spectroscopy 
and HR-MS. 
 Establish an inexpensive, rapid, high through-put method for the preliminary 
assessment of the selective effects and cytotoxicity of the prepared compounds 
using cell counts, metabolic assessment (MTS assay), imaging using flow 
cytometry, and fluorescence microscopy using dyes (especially supravital staining 
with propidium iodide which is claimed to be useful in distinguishing live from 










HYPOXOSIDE: EXTRACTION, ISOLATION AND SYNTHESIS OF 
TWO DERIVATIVES 
2.1 OVERVIEW 
Plants produce phytochemicals, many of which have associated medicinal properties. Natural 
products have gained importance as being a possible primary source of commercial drugs 
(Chin et al., 2006) . Many older drugs are derived from plants e.g. cocimadin from sweet 
clover, aspirin from the bark of the yellow white willow and the malaria drug artemisinin 
sourced from Artemisia annua L. Many of the most effective cancer drugs are also derived 
from plants, e.g. vincristine, etoposide and paclitaxel that were isolated from the periwinkle, 
May apple and pacific yew tree, respectively. 
For centuries in Africa, traditional healers were the only source of medical assistance for 
illness and diseases. Traditional healers use parts of plants for treatment of these diseases. 
Aqueous extractions of Hypoxis corms, for example, were traditionally used for intestinal 
parasites, barrenness, impotency, bad dreams, insanity and cardiac ailments. Since more 
diseases are now known, the Hypoxis extract has been used for treatment of cancer, 
headaches, dizziness, for testicular tumours, prostate hypertrophy and to boost the immune 
system (Drewes et al., 2008) . Hypoxis hemerocallidea is well known in Southern Africa. 
This plant is distributed in the wild areas from Eastern Cape, KwaZulu-Natal, Limpopo and 
Zimbabwe and has been chosen for this study because it has been reported to have a high 
concentration of hypoxoside compared to other Hypoxis species. A study carried out by 
Boukes et al. (2008) reported that 5 mg of H. hemerocallidea extract was found to contain 
12.7 µg of hypoxoside, while H. stellipilis and H. sobolifera contained 7.9 µg and an 
undetectable amount, respectively (Boukes et al., 2008).  
As the Hypoxis extract became better known amongst the South African people, local 
entrepreneurs have prepared Hypoxis extracts for dispensing over-the-counter (OTC). These 
are readily available in pharmacies, health shops and supermarkets. Moducare® is one such 
product. The secret of Moducare® is that it contains the two sterols isolated from the Hypoxis 
extract (i.e. β-sitosterol and its glucoside). These are mixed in a given ratio to enhance human 
T cells growth (Boukes and Venter, 2012). Hypo Plus is also marketed as an OTC food 
supplement and immune booster. It consists of a Hypoxis extract, as well as a range of amino 
acids, vitamins and anti-oxidants. The Impilo African Potato product is also an OTC 
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preparation in a form of either a tablet or the capsule and is prepared from a Hypoxis extract 
(Drewes and Khan, 2004) . 
The biological activity of the Hypoxis extract was initially associated only with steroid 
glycosides (Bettolo et al., 1982; Laporta et al., 2007a; Nair and Kanfer, 2006). Isolation of 
the active components from the crude extract is always important, as it reduces the possible 
negative effects of the other associated toxins or harmful compounds. The active principle 
was found to be hypoxoside and this was firstly isolated by Bettolo et al. (1982). Hypoxoside 
is referred to as a pro-drug as it is biologically inactive in it‟s isolated form, but, as discussed 
in Chapter 1, it can be hydrolyzed to its active form, referred to as rooperol, by the enzyme β-
glucosidase (Drewes et al., 1984; Nair et al., 2007).  When β-glucosidase reacts with 
hypoxoside it is converted to the biologically active rooperol through the removal of the two 
sugar groups linked at their anomeric position to the benzene rings of hypoxoside (Figure 
1.2). This enzyme has been reported several times to be present in tumours and hence 
tumours may activate this compound to their own detriment (Smit et al., 1995). When 
hypoxoside is ingested (in vivo) it is converted to rooperol as there is a high content of 
activated β-glucosidase in the colon (Kruger et al., 1994). On ingestion of the hypoxoside the 
compound is activated and may be absorbed to perform its curative role. 
Hypoxis extracts have been studied for a number of ailments but more needs to be done to 
verify the claims by traditional healers and others. The phase I anti-cancer trial of hypoxoside 
carried out by Smit et al. (1995) did not show a significant effect on lung cancer patients, 
although patients were treated with high concentrations of hypoxoside. Subsequent reports on 
rooperol indicate that it has a strong antioxidant ability with a strong ability to inhibit lipid 
peroxidation (Laporta et al., 2007b) . The hypoglycemic effect of the African potato extract 
was also reported but the active component causing this effect has not been identified (Zibula 
and Ojewole, 2000). The cardiovascular studies suggest that Hypoxis extract may be used as a 
natural treatment for some cases of cardiac dysfunctions and for hypertension (Ojewole et al., 
2006). The anticancer activity of the H. hemerocallidea extract on Hela, MCF7 and HT27 
cell lines showed it to have a lower anticancer activity than the anticancer activity of the H. 
sobolifera, a plant that has the lowest content of hypoxoside (Boukes et al., 2008). The 
reason for this was not stated. 
The aim of the current study was to isolate hypoxoside from Hypoxis hemerocallidea, and, in 
addition to hypoxoside, prepare two further derivatives from the pure hypoxoside, and 
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subsequently to investigate their selective cytotoxicity against a normal (MCF10A) and a 
premalignant (MCF10A-NeoT) breast epithelial cell line. Similar work has been done on the 
Hela, HT-29 and MCF-7 cancer cell lines, respectively. This showed that hypoxoside has 
cytotoxic effects on cell lines such as cervical, lung and breast cancer cell lines (Boukes and 
Van de Venter, 2011). The current research will be different in that two derivatives, the 
dimethylhypoxoside (DMH) and decaacetylhypoxoside (DAH) previously prepared by 
Bettolo et al. (1982) have been prepared from hypoxoside, and further tested against both a 
normal and a premalignant invasive breast epithelial derivatives. These derivatives have 
never been evaluated for their activity, but were evaluated in the hope of finding better anti-
cancer compounds for the treatment of invasive breast cancers.  
In order to perform the derivatization and ensure the correct compound and plant corm was 
extracted, the plant had to be collected and identified. 
2.2 COLLECTION AND IDENTIFICATION OF THE CONSTITUENTS IN H. 
hemerocallidea  
Hypoxis hemerocallidea (Figure 2.1) corms were collected from the Hayfields commonage 
along Military Way, Pietermaritzburg and identified by Dr Christina Potgieter of the John 
Bews Herbarium, School of Life Sciences, University of KwaZulu–Natal, Pietermaritzburg 








Figure 2.1: Corm and flower of the collected Hypoxis hemerocallidea (photographed by 
Prof S.E. Drewes). 
2.3 EXTRACTION AND ISOLATION 
There is a growing demand for the pharmaceuticals based on medicinal plant extracts. The 
market volume of herbal extracts for food additives amounted to Euro 6.7 billion in Europe 
for 2003 alone and Euro 17.5 billion in the world. Continuous demand spontaneously drives 
the task of developing new and effective extraction methods (Ivanov et al., 2006).  
There are many methods that have been developed throughout the world for commercial 
extraction of plant materials. The general techniques include maceration, infusion, 
percolation, digestion, decoction, hot continuous extraction (Soxhlet), aqueous-alcoholic 
extraction by fermentation, counter-current extraction (CCE) and supercritical fluid 
extraction (Golovanchikov and Popov, 1998). 
Extraction of the components from traditional plants in traditional medicine is generally 
based on extraction with various solvents at room temperature or on heating (Golovanchikov 
and Popov, 1998).  
2.3.1 Materials and equipment 
The reverse-phase column (3.5 x 2.7 cm) used in this study was a product from Phenomenex. 
The solvent used for extraction was ethanol (Merck), for isolation of hypoxoside, methanol 
(Merck) was used, a mixture of n-butanol (Kleber chemicals), H2O, toluene (Merck) and 
MeOH (Merck) was used for identification of hypoxoside using TLC (silica gel 60 F254, 
Merck, Germany). The separation was effected with cartridges packed with C-18 reverse-
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phase silica using a standard vacuum manifold assembly. Chemicals used for methylation 
were methylamine (BHD Laboratory reagents), sodium nitrite (Sigma), urea (Saarchem), 
hydrochloric acid (Merck), sulfuric acid (Merck) and potassium hydroxide (Saarchem). The 
acetylation procedure was carried out with the following compounds: pyridine (Saarchem), 
acetic anhydride (Merck), followed by drying with anhydrous magnesium sulfate (Merck). 
For obtaining the extract in a solid form, it was freeze dried using a VirTis machine 
(Polychem Supplies). For characterization of hypoxoside and its derivatives, a Bruker NMR 
spectrometer (500 MHz) and Waters Micromass LCT Premier TOF mass spectrometer were 
used. 
2.3.2 Extraction and isolation procedures 
This part of the work was performed in the Department of Chemistry in the University of 
KwaZulu-Natal, Pietermaritzburg. The extraction was done according to the method used by 
Drewes et al. (1984) with a few modifications. Freshly collected corms (1.65 kg) of Hypoxis 
hemerocallidea were thoroughly washed under running tap water. They were cut into thin 
slices, macerated and subsequently soaked in ethanol (2 L) at room temperature for 48 h. The 
extract was filtered and concentrated in vacuo, followed by freeze drying to give 
approximately 56 g of brown residue. Thereafter, 200 mg of the crude material was dissolved 
in a MeOH-H2O (1:1) mix and separated on a pre-packed C-18 reverse-phase column 
(Phenomenex 3.5 x 2.7 cm) using a standard vacuum manifold assembly. The isolation 
procedure was repeated five times. Hypoxoside was detected in the fractions by TLC using 
an n-butanol-H2O-toluene-MeOH (4:2:2.5:2) solvent system and para-anisaldehyde for 
visualization. Fractions containing a single compound were combined and concentrated in a 
rotary evaporator. The resultant aqueous fraction was freeze dried to give pure hypoxoside 
(~100mg). The purity and structure of hypoxoside was confirmed with NMR spectroscopy. 
The experiments used were 1H NMR (for identification of protons), COSY45 (correlated 
spectroscopy, a 2-D NMR experiment that reveals correlation between neighboring protons), 
13C NMR (to identify all carbons), DEPT (distortionless enhancement polarization transfer, to 
distinguish CH3 from CH‟s and CH2‟s, carbons), and heteronuclear single quantum coherence 
(HSQC) and, heteronuclear multiple bond correlation (HMBC) experiments to detect 




Table 2.1: Collected masses of the hypoxoside and derivative weights. 
 Material type      Mass (g unless otherwise stated)   
1. Fresh corms 1650  
2. Crude extract 56.6 (3.4%) 
3. Hypoxoside 291 mg (yield from 1 g crude extract, therefore 29% was produced)  
Table 2.1 shows the mass of the isolated products and hypoxoside. A good separation of the 
major product was achieved using a reversed phase column chromatography, as indicated by 
examination by TLC, though minor contamination was present in the initial fractions (Figure 
2.2).  
 
Figure 2.2: TLC plate showing fractions collected from a reverse phase 
chromatography column in the manifold assembly. 
The spots of the collected fractions were plotted on the TLC plate and the tubes 6, 7, 8, 9 and 10 
were used for derivatization. The 1st spot represented with an “s” is the starting material before it 
was introduced on the column. The second spot represented by 3 was the 3rd fraction collected 
from the column and the fractions were collected up to the 12th tube/fraction.  
2.3.4 Elucidation of the hypoxoside structure by 1H and 13C NMR spectroscopy 
The structure of the hypoxoside isolated and selected, as described above, was confirmed by 




The isolated hypoxoside was diluted with deuterated methanol (approximately 2 ml) and the 
1H and 13C NMR spectra recorded at 500 MHz and 125 MHz, respectively (Bruker 
Instrument). In order to allocate all protons and carbons in the spectra, use was made of two-
dimensional NMR experiments such as COSY, DEPT, HSQC and HMBC to identify the 
position and relationships of the relative atoms. 
2.3.4.2 Results 
The analysis of the spectra is shown in Table 2.2 below (all spectra shown in Appendix A). 
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6.57 (1H, d, J = 15.7 Hz) 
6.13 (1H, dt, J= 15.7; 5.0Hz) 




6.92 (1H, d, J= 2.1 Hz); 6.90 (1H, d, J=2.1 Hz) 
- 
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7.12 (2H, d, J = 8.3 Hz) 
6.87 (1H, dd, J= 8.3; 2.1 Hz); 6.82 (1H, dd, J=8.3; 
2.1 Hz) 
 







































































Figure 2.3: Numbering of carbons in the hypoxoside structure.  
The two benzene rings are separated by a chain of five different carbons (single, double and 
triple bond). This causes the protons on one ring to have slightly different chemical shifts to 
those on the other ring, but the splitting patterns (AMX) remain the same. The ring that will 
have more deshielded protons will be the one closer to the triple bond. In the region δH 6.8-
7.2, the six protons present on the two benzene rings confirm the hypoxoside structure as 
follows: the first doublet peak at δH 7.12 shows protons 5׳5/׳׳, overlapping exactly with 
coupling constant of J=8.3 Hz (ortho-coupling). The second two doublet peaks at δH 6.92 and 
6.90 represent the 2 ׳ ׳ protons. The third set of peaks at δH 6.82 and 6.87 represent the 6 ׳2/ ׳׳  ׳6/
protons, shown as a double pair of doublets due to the ortho-splitting by H-5 ׳׳ -and meta ׳5/
splitting by H-2 ׳׳  Overall the protons are a clear example of the AMX pattern in which two .׳2/
systems are imposed on one another. 
From the 5 carbon chain linking the two benzene rings, three protons can be seen. The proton 
on C1 resonates at δH 6.57 as a doublet with J = 15.7 Hz (trans configuration). The proton on 
C2 resonates at δH 6.13 and is a doublet of triplets (as anticipated) with J = 15.7 and 5.0 Hz. 
The protons on C3 (CH2) resonate further upfield at δH 3.29. 
The only CH2 groups in the molecule (at C-3, and at C-6 on glucose) were readily located 
from the DEPT analysis. The proton spectrum is well resolved and much clearer than the 
original spectrum produced by Marini Bettolo and his co-workers in 1982 (Bettolo et al., 
1982) . The 13C NMR shift values listed in Table 2.2 are in good agreement with the values 
quoted earlier (Bettolo et al., 1982). 
2.4 PREPARATION OF HYPOXOSIDE DERIVATIVES 
The numerous uses of the Hypoxis extract have drawn much interest in the synthesis and 
derivatization of rooperol, the biologically active form of the Hypoxis extract‟s major 
compound, hypoxoside. Initially, when hypoxoside was isolated, three derivatives were made 
from hypoxoside (i.e. decaacetylhypoxoside, dimethylhypoxoside and dimethyloctaacetyl 
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hypoxoside) and other derivatives were made from rooperol which include the tetramethyl 
aglucone and tetraacetyl aglucone (Bettolo et al., 1982). None of these compounds have been 
tested for biological activity and the current research was carried in the hope that the 
derivatized compounds had increased anticancer activity compared to the parent compound. 
A patent filed in 1987 contains a number of rooperol analogous and related compounds. 
Selected compounds recorded in the patent were tested against selected cancer cell lines and 
rooperol was found to have the best selective toxicity against most cancer cell lines (Drewes 
and Liebenberg, 1987). These derivatives where not, however, those investigated in the 
current study i.e. DMH and DAH. 
2.4.1. Methylating hypoxoside 
In order to prepare the dimethylhypoxoside, nitrosomethylurea, precursor for the 
diazomethane procedure, needed to be prepared. Diazomethane is a well-known methylating 
agent. 
2.4.1.1 Preparation of nitrosomethylurea (diazomethane precursor) 
The nitrosomethylurea was prepared according to Arndt et al. (1935) with no modifications 
(Arndt et al., 1935). 
2.4.1.2 Precursor preparation procedure 
A 33% aqueous solution of methylamine (145 g) and an aqueous solution of 32% 
hydrochloric acid (~155 ml) were mixed in a 1 l flask, with the acid added until the solution 
was acidic to methyl red. Water (~100 ml) was added to bring the total volume to about 500 
ml. The solution was mixed with urea (300 g) and boiled under gentle reflux for 2.75 h and 
vigorously refluxed for a further 15 min. The solution was cooled overnight at room 
temperature (~ 15oC) and a 2% (m/v) sodium nitrite (10 g) was dissolved in the cooled 
solution (500 ml), which was further cooled to 0oC. A mixture of ice (600 g) and a 98% 
sulfuric acid (54 ml) was placed in a 3 l beaker surrounded by sufficient freezing mixture (ice 
mixed with coarse salt). The cold methylurea-nitrite solution was slowly poured into the 
H2SO4-ice mixture with mechanical stirring. The temperature was not allowed to rise above 




2.4.1.3 Methylation step of hypoxoside 
The nitrosomethylurea prepared in Section 2.4.1.1 was used to prepare the diazomethane 
popularly known as a methylating agent to produce the required methylated hypoxoside 
derivative (DMH). 
2.4.1.4 Methylation procedure 
A 40% (m/v) aqueous solution of KOH (15 ml) was added to diethyl ether (80 ml) while 
stirring. The mixture was surrounded by an ice bath at 0oC. Nitrosomethylurea (4 g) was 
added to the KOH/ether solution in small portions while stirring and keeping the temperature 
at 0oC. When the bubbling was complete the yellow upper layer was transferred into a conical 
flask with KOH pellets (stored at 0oC) in order to dry the ether layer. The ether layer was 
transferred into a second flask with KOH pellets and was left there for 10 minutes. The 
hypoxoside (100 mg) was dissolved in methanol (10 ml) and allowed to cool to 0oC. The 
yellow ethereal solution of diazomethane was subsequently poured into a methanolic solution 
of hypoxoside. The mixture was stored at 15oC for up to 4 days. The TLC examination 
showed a single component and the product was subsequently concentrated in vacuo. The 
material was dissolved in distilled water and freeze dried to give dimethylhypoxoside (107 
mg).  
The DMH produced was subsequently analyzed by 1H NMR and to further confirm the 
identity of DMH, a high-resolution mass spectrum (HR-MS) was run (Waters Micromass 















































From 100 mg hypoxoside, 107 mg of DMH was obtained. The DMH derivative differs from 
hypoxoside only in the fact that the two free OH groups on the aromatic rings have been 
methylated. The proton NMR spectrum is virtually super-imposable on that of hypoxoside 
apart from the fact about the strong methoxy signals (2 x OMe) found at δH 3.95. This was 
further confirmed with the high-resolution mass spectrometry (HR-MS) results as follows: 
Calculated mass for C31H38O14Na = 657.2159 g/mol. (Na+ adduct formed in mass 
spectrometer) 
Observed mass of the derivative = 657.2153 g/mol. 
2.4.2 Acetylation of hypoxoside 
 
Acetylation of hypoxoside and acetylation of hypoxoside was carried out as described by 
Bettolo et al. (1982). 
2.4.2.1 Procedure 
A 1:1 mixture of pyridine and acetic anhydride (4 ml) was prepared. The hypoxoside (100 
mg) was added to the mixture and allowed to stand for 72 h. Distilled water (10 ml) was 
added and a white precipitate formed. The product was extracted with ethyl acetate and two 
layers formed, which were separated. The aqueous layer was further extracted with ethyl 
acetate. The ethyl acetate extracts were dried over anhydrous magnesium sulfate and 
concentrated in the rotary evaporator at 50oC for 30 min. A small amount of pyridine was 
left, to which 20 ml distilled water and few drops of 32% (v/v) HCl were added. The solution 
was again extracted with ethyl acetate, dried over magnesium sulfate and concentrated to 
dryness at 50oC. 
The DAH produced was subsequently analyzed by 1H NMR and to further confirm the 



















































Figure 2.5: Numbering of carbons in the decaacetylhypoxoside structure. 
Treatment of hypoxoside with acetic anhydride/pyridine afforded the decaacetyl derivative 
(109 mg of DAH from 100 mg hypoxoside). It was clear that acetylation of the eight hydroxy 
groups on the glucose moieties as well as the two free phenolic groups at the C-3׳׳ and C-3׳ 
positions had taken place. The 1H NMR spectrum is closely related to that of the HYP for 
most of the protons, but also revealed a strong acetyl signal at 2.1 ppm (10 x OCOCH3) as a 
sharp multiplet. The final confirmation of the structure came from the high-resolution mass 
analysis.  
 
Calculated mass for C49H54O24Na = 1049.2903 g/mol. 
Observed mass of the derivative = 1049.2903 g/mol. 
 
The HYP, DMH and DAH derivatives prepared were now considered suitable for subsequent 
testing for their selective cytotoxicity on the model cancer cell lines selected for the current 















ASSESSMENT OF ANTI-CANCER SELECTIVE CYTOTOXICITY OF 
THE HYPOXOSIDE AND TWO DERIVATIVES 
3.1 INTRODUCTION 
 
The main goal of chemotherapy is to adversely affect cancer cells and leave the normal cells 
unaffected. Assessment of the relative toxicity of drugs on normal and abnormal cells is 
important and this is called the assessment of “selective cytotoxicity” (Crawford et al., 2003; 
Yang et al., 2011). A problem faced is that selective cytotoxicity may depend on cell type, 
i.e. a drug may be selectively toxic to a certain normal cell or one kind of cancer cell and not 
to another (Henderson, 1969). 
 
Cancer cells, however, go through marked molecular changes during transformation from 
normal to malignant cells and such changes may fortuitously bring susceptibility to specific 
cytotoxic drugs. Some genes have been identified to be associated with a specific cancer 
phenotype and identifying such molecular changes or genes may assist in drug choice (Simon 
et al., 2000). A study of genes that contribute to the sensitivity of the cancer cells to anti-
cancer drugs has been carried out in yeast cells, but how reliable and valid such a study may 
be questionable due to cell differences (Simon et al., 2000). The availability of a unique 
normal and premalignant breast epithelial test cell line model, the MCF10A and MCF10A-
NeoT cell lines (Section 1.4.2 and 1.4.3), in which the effect of specific cancer progression-
inducing mutations, e.g. transformation with the (Val-12) mutationally activating H-ras 
oncogene may be tested, has given rise to a much more suitable system and has been used 
extensively for this purpose to date (Miller et al., 1993). 
 
Single-stranded DNA-drug constructs (anti-cell aptamers) that specifically bind to the surface 
of a certain type of cancer cell have been developed. When polymerized with a synthetic 
linker, “acrydite”, and conjugated with the novel drug, binding and being internalized by 
target cells may cause sensitive cells to die (Yang et al., 2011). Such a new approach 
represents one possible strategy for specifically targeting a specific tumour type, known to be 
sensitive to a particular drug. 
 
Malignant tumours are different to normal cells in that as they grow into large disordered 
masses and they are, therefore, soon deprived of oxygen supply from blood vessels. 
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Adaptation to growth under such conditions assists malignant tumour survival. This is 
promoted by a protein known as hypoxia-induced factor-1 (HIF-1) which stimulates 
angiogenesis, expression of glucose transporters and glycolytic enzymes and also promotes 
glycolysis to produce lactate. This allows cancer cell survival under anoxic conditions via the 
Warburg metabolic route, while blocking mitochondrial oxidative phosphorylation and 
production of reactive oxygen species (ROS) by mitochondria as excess ROS is damaging 
(Nagy, 2011). Hypoxic cells produce ROS but low levels are found to stabilize HIF-1 under 
anoxic conditions. HIF-1, therefore, prevents pyruvate entering the TCA cycle, and oxidative 
phosphorylation, through the induction of an inhibitor protein, kinase D-1 (PDK-1), 
facilitating survival of cancer cells (Nagy, 2011). 
 
HIF-1 expression, therefore, changes the metabolism of cancer cells to alleviate ROS stress 
and, to compensate for the inefficiency of Warburg metabolism. Cancer cells also try to 
ensure survival by stimulating glutaminolysis to provide compensating ATP energy. As the 
deglycosylated derivative of hypoxoside, rooperol is described to have anti-oxidant activity 
(Laporta et al., 2007b), treatment with hypoxoside (converted to rooperol after oral uptake), 
may stress the cancer cells as total neutralization of ROS may destabilize HIF-1 activity. It is 
thought that rooperol may, therefore, have therapeutic potential, potentially allowing 
malignant tumours to be selectively targeted, as they, and not normal cells, survive using the 
Warburg metabolic pathway. For this reason, purified Hypoxis extract (hypoxoside) and two 
derivatives were tested for their selective cytotoxicity on the normal MCF10A breast 
epithelial cells and the H-ras transfected premalignant MCF10A-NeoT derivative, as a model 
of a normal and premalignant breast epithelial cell, in the progression to invasive cancer. 
HIF-1 is also responsible for the induction of cell migration and invasion as is the 
mutationally activated H-ras (Kim, 2007). 
3.2 HYPOXOSIDE AND TWO DERIVATIVES AS POTENTIAL ANTI-CANCER 
DRUGS 
 
As activation of H-ras has been associated with upregulation of the invasive phenotype 
(Moon et al., 2000) and HIF-1 is associated with an increased Warburg effect, and an 
invasive phenotype, the H-ras transfected MCF10A derivative seems to give rise to a suitable 
model on which to screen hypoxoside and its derivatives for activity for effect on breast 
cancers with a similar profile. Two derivatives, as well as hypoxoside, were tested as 
hypoxoside from other AP species has been tested on cancer cell lines before, with some 
success (Boukes, 2008; Boukes et al., 2010; Boukes and Van de Venter, 2011) but with little 
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success in clinical trials (Albrecht et al., 1995a; Albrecht et al., 1995b; Boukes, 2008; Boukes 
et al., 2010; Boukes and Van de Venter, 2011). The two derivatives of hypoxoside from H. 
hemerocallidea that have been synthesized for this study have never been tested previously.  
 
A high-throughput preliminarily screening method was also sought. PI methods have been 
specifically mentioned to be suitable for the assessment of early and late apoptosis, as well as 
necrosis (Zamai et al., 2001). Effects of test compounds on metabolism (O'Toole et al., 2003) 
(i.e. MTS assay) and also cell numbers were explored in the current study. As such a study 
constitutes a “range find” assessment for further future investigations, an exposure time that 
was both convenient, time efficient, and yet considered long enough to assess effects, was 
chosen to allow at least early effects and trends to be established (Malich et al., 1997). 
Though some studies extend the exposure time to approximately 72 h (O'Toole et al., 2003), 
since a rapid and preliminary cytotoxicity assessment of the prepared hypoxoside and its 
derivatives was required, a 24 h exposure was chosen. In order for such a test to be 
completed, however, the more hydrophobic derivatized compounds had to be initially 
solubilized in an organic solvent at a non-toxic level. So that the solvent effect could be 
maintained as low as possible, a dilution series of the test compounds was established to 
maintain solvent levels at a constantly low, non-toxic level. 
3.3 EXPERIMENTAL 
3.3.1 Materials and equipment 
 
MCF10A and MCF10A-NeoT cell lines were supplied by Prof Sloane (Department of 
Pharmacology, Wayne State University, Detroit, MI). The chemicals used were of the highest 
purity available (analytical reagents). Cells were cultured in Dulbecco‟s modified Eagle‟s 
medium (DMEM)-Ham‟s F12 nutrient medium from Sigma (St. Louis, Mo, USA) containing 
5% horse serum and Fungizone was purchased from Gibco (Paisly, UK), and supplemented 
with insulin and hydrocortisone from Sigma (St. Louis, Mo, USA), and recombinant human 
epidermal growth factor purchased from Upstate Biotechnology (Lake Placid, USA). Hank‟s 
balanced salt solution (HBSS), phenazine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), dimethyl sulfoxide 
(DMSO), acridine orange, propidium iodide, cyclohexamine, sodium bicarbonate and 
trypsin-ethylenediaminetetra-acetic acid were all purchased from Sigma Aldrich (St. Louis, 




The absorbance was read using a Fluostar OptimaVersamax (Labtech, Taiwan). Cell counts 
were performed using a Beckman Coulter Epics XL flow cytometer or improved Neubauer 
haemocytometer counting chamber. Dead or alive cells were distinguished using AO/PI 
staining. Staining was viewed using the Olympus Provis AX70 fluorescence microscope and 
AnalySiS v3.0 Soft Imaging System, colour view camera and software. Cells were also 
viewed under an Olympus inverted light microscope during culture.  The sterile cell culture 
flasks (25 and 75 Ti), and 96 and 24 Transwell tissue culture plates, 15 and 50 ml screw top 
Falcon tubes, round coverslips (30 mm) and micropipettes were from Nunc (Roskilde, 
Denmark) or Bibby-Sterilin (Staffordshire, UK). 
3.3.2 Preparation of the stock and working solutions of hypoxoside and hypoxoside 
derivatives 
 
All the derivatives of hypoxoside produced were soluble in ethyl acetate but this solvent is 
toxic to cells. The most common solvent used in dissolving compounds for cell culture 
purposes, due to its low cell toxicity at low temperatures, is dimethyl sulfoxide (DMSO). 
This solvent is, therefore, usually used to preserve and store cells in liquid nitrogen, as it 
protects them against ice crystal damage at lower temperatures. It is also known to trap free 
radicals and is often used as a free radical scavenger. It is still poisonous at temperatures 
above -80oC, however, and has been reported to decrease viability of cells via the up-
regulation of the apoptosis promoter BAX at 1% DMSO in media (Cao et al., 2007). For this 
reason levels of DMSO should be kept as low as possible (and below 1%) and exposure of 
cells limited by dilution or washing of cells as soon as possible. This is especially true on 
thawing of cells stored in liquid nitrogen to which the freezing medium (20% horse or bovine 
serum, 10% DMSO and 70% culture medium) is added prior to freezing. 
 
Though HYP and DMH were soluble in aqueous media, the DAH was not completely soluble 
in such a solvent. It was, therefore, decided to dissolve all the compounds [hypoxoside 
(HYP), and the two derivative dimethylhypoxoside (DMH) and decaacetylhypoxoside 
(DAH), synthesized from hypoxoside as described in Chapter 2], in the lowest final 
concentration of DMSO possible. 
 
The three compounds were dissolved completely in pure DMSO. As the % of DMSO that the 
MCF10A cells can withstand without any cytotoxic effects was established to be 
approximately 0.001% DMSO (unpublished results), this required the development of a 
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complex dilution series so that all compounds were dissolved in the same final % of DMSO 




Hypoxoside stock solution (300 mM) 
Hypoxoside (18 mg) was dissolved 100 µl of pure DMSO in a 100 µl cryo-vial (making up a 
stock solution of 300 mM) and stored at 0oC. 
 
Dimethylhypoxoside stock solution (300 mM) 
Dimethylhypoxoside (19 mg) was solubilized in a 100 µl cryo-vial tube, making up a final 
stock solution of 300 mM, and stored at 0oC. 
 
Decaacetylhypoxoside stock solution (300 mM) 
Decaacetylhypoxoside (15.4 mg) was dissolved in 50 µl in DMSO resulting in a final stock 
solution of 300 mM and stored at 0oC. 
3.3.2.2 Procedure 
 
Stock and working solutions of hypoxoside and its various derivatives were prepared as 
illustrated below (Fig 3.1) in an effort to maintain the overall concentration of potentially 
toxic DMSO at a minimum, while achieving a concentration of 4.8-300 M of the various 
test drug derivatives. The dilution series from 300 µM to 19 µM (Figure 3.1) was made by 
adding 100 µl of hypoxoside or 100 µl for DMH or 50 µl for DAH stock solution, and 
DMSO into cryo Eppendorf tube (containing 100 or 50 µl of DMSO, respectively) to make 
300 mM stock solution.  
 
To make up the a dilution series from this stock solution, serial double dilutions (300 mM to 
19 mM) in DMSO were carried out (Figure 3.1, top row), and were extended to produce a 
9mM- down to a 4.8 mM concentration in a similar manner (details not shown) and used to 
make working solutions, or stored at 5oC. The working solutions were prepared by aliquoting 
3 µl of each stock solution and diluting it with 3000 µl DMEM: F-12 complete media (1 in 





Figure 3.1: The preparation of solutions of hypoxoside and derivatives.  
 
Stock solutions were prepared in 100 µl cryo Eppendorf tubes in 100% DMSO, as described in 
Section 3.2.2.2, from the highest concentration (300 mM) using a 1:1 serial dilution in DMSO to 
produce a 4.8 mM, lowest concentration. To produce the final working concentration the initial 
stock solution (top row) was diluted in a 1/1000 dilution with DMEM: F-12 complete media 
resulting in an equivalent µM unit concentration.  
 
These dilutions were dispensed into multiwell plates seeded with subconfluent monolayers of 
MCF10A and MCF10-NeoT cells. 
 
3.3.3. Culturing MCF10A and MCF10A-NeoT cell lines  
 
Use of cell cultures has made preliminary testing of drugs far easier by removing ethical and 
statistical problems associated with animal models. Replicates and many cells may be 
assessed, though the behaviour of such cells may not be a highly representative of cells in 
vivo.  
 
The first human cancer cell line to be established, over 50 years ago, was the immortal 
Henrietta Lacks (HeLa) cell line, isolated from a young black woman with cervical cancer. 
Over a thousand cell lines have been used as a tool to study the biochemistry and molecular 
biology of cancers. These have also assisted in understanding of cancer and normal cell 
behavior (Langdon, 2004). 
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The MCF10A was isolated from the patient with fibrocystic breast disease cells but has 
normal epithelial cell characteristics (Soule et al., 1990; Tait et al., 1990), though these cells 
are immortal. The MCF10A-NeoT derivative, established by transfection with the c-Ha-ras 
proto-oncogene, converted into a mutationally activated oncogene by a VAL-12 mutation 
(Basolo et al., 1991; Calaf et al., 1995) has been reported to give rise to premalignant cell 
characteristics (Russo et al., 1991). When these two cell lines are used together, as they are 
from the same genetic source, they most validly, of all models, allow assessment of the test 
compounds on a near normal and premalignant breast cancer cell. Further derivatives 
harbouring further mutations, replicating the progression to a malignant phenotype are also 
available (Miller et al., 1993). Here we limit testing to the MCF10A and MCF10A-NeoT 
cells, usually used as models of normal and premalignant cell lines, respectively. This is a 
good model because the “normal” cell line is used to establish the baseline levels of drug 
non-toxic to normal cells but toxic to premalignant cells of the same genetic background, i.e. 
selective cytotoxicity levels. 
 
Cell culture is widely practiced worldwide and it involves allowing the cells to grow and be 
maintained outside the body. The cell culture techniques have been developed over many 
years. The cells need nutrients supplements to survive outside the body, and they are usually 
cultured in a basic media, complemented with some additives. The basic media usually 
contains amino acids, glucose, salts, vitamins and other nutrients. The additives include L-
glutamine (mostly included in the basic media), antibiotics (streptomycin and penicillin 
usually used), growth factors, antimycotics and serum, and the pH is carefully controlled by a 
bicarbonate buffering system (Phelan, 1996). The choice of culturing medium is selected 
after experimentation and according to the experience during establishment of the cell line 
(Phelan, 1996).  
 
For the MCF10A and it derivative cell culture, the DMEM: F-12 basic media was used and it 
was supplemented with horse serum, insulin, hydrocortisone, penicillin/streptomycin, 
epidermal growth factor, as illustrated in the following section. 
3.2.3.1 Reagents 
 
DMEM: Ham‟s F-12 incomplete medium. 
Commercially pre-weighed medium and sodium hydrogen carbonate (1.2 g) were dissolved 
in distilled water (≈ 900 ml) using a magnetic stirrer. The pH was adjusted to 6.9 ± 0.3 range 
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if necessary and the solution made up to 1 L with distilled water. Sodium carbonate (1.2 g) 
was added to the solution and allowed to completely dissolve. The medium was filter 
sterilized and aliquoted into 200 ml sterile quanta and incubated at 37 oC overnight to check 
for contamination. The media was stored at 5 oC, but incubated at 37 oC before use. 
 
Hank‟s balanced salt solution (HBSS). 
Commercially pre-weighed HBSS powder was dissolved in distilled water (900 ml), stirred 
with a magnetic stirrer to ensure dissolution, sodium carbonate (0.35 g) was added and the 
pH was adjusted within a range of 7.3 ± 0.3 with HCl or NaOH if necessary. HBSS was filter 
sterilized into autoclaved bottles and incubated at 37oC to assess contamination, before 
storage at 5oC. 
 
Horse serum. 
Commercially available bottles of horse serum were incubated on a water bath at 56oC for 30 
minutes to denature compliment components. The horse serum was aliquoted into 10 ml 
volume in a 15 ml Falcon tube and stored at -20oC. 
 
Insulin. 
The prepared HBSS (16.5 ml) was used to dissolve insulin (10.2 mg) with the addition of 0.1 
M NaOH (500 µl) and stored at -20oC before used.  
 
Epidermal growth factor (EGF) (50 µg/ml) 
Sterile EGF (100 µg) was aseptically dissolved in autoclaved Milli-Q water (2 ml) and stored 
at -20oC. 
 
Hydrocortisone (3.33 µg/ml) 
Hydrocortisone (10 mg) was dissolved in absolute ethanol (3 ml) and stored at -20oC. 
 
DMEM: Ham‟s: F-12 complete medium. 
The incomplete medium was supplemented with the decomplemented horse serum (10 ml), 
insulin (3 ml), fungizone (2 ml), EGF (80 µl) and hydrocortisone (30 µl). Then the complete 





Fungizone (250 µg/ml) 
Fungizone (5 mg) was dissolved in distilled H2O (20 ml) and was subsequently stored at  
–20oC and will be defrosted to 37oC before use. 
 
Penicillin/Streptomycin. 
Pen/strep was commercially prepared and used as prescribed. 
 
1 x Trypsin-EDTA. 
Commercially available 10 x trypsin-EDTA (1 ml) was aliquoted in 15 ml Falcon tube and 
stored at -20oC. When about to use the aliquots were incubated at 37oC and subsequently 
diluted in a 1:10 dilution with prepared HBSS (9 ml). 
3.2.3.2 Procedure 
 
The cells were cultured (37oC, 5% CO2/70% relative humidity) in a H2O jacketed incubator 
(Nuaire, US Autoflow) in 25 or 75 Ti culture flasks for 3-4 days. When cells reached 70% 
confluence they were passaged by washing with HBSS, covering the monolayer with trypsin-
EDTA (± 1 ml) and incubation (37oC, 5% CO2, approximately 15 min). To detach the cells, 
they were given a gentle tap with the palm of the hand and checked with an inverted light 
microscope every 7 minutes to assess complete detachment of cells. The complete DMEM: 
Ham‟s F-12 (10 or 20 ml of medium, respectively, depending on the capacity of the culture 
flask) was, subsequently added to neutralize the trypsin-EDTA. The suspension was split into 
two Ti (25 or 75) culture flasks (1:2). 
 
It is important to freeze down stock cells before they become fully confluent and keep 
passage numbers low (to prevent genetic “drift”, especially as the MCF10A cell line has a 
p53 mutation). Freezing the cells involves trypsinizing (1 ml) the actively growing cells 
allowing them to dislodge When the cells have dislodged, an ice cold media (1 ml) consisting 
20% horse serum, 10% DMSO and 70% media was introduced to the cell suspension. The 
cell suspension was aliquoted into 4 cryovials (0.5 ml each) and immediately transferred to a 






3.3.4. MTS Assay optimization, compound exposure and data analysis  
 
The availability of various cell lines of various types has allowed drugs for specific purposes 
to be tested at least in a preliminary way. Though the MTS assay is known as a cytotoxicity 
assay, it actually measures metabolic activity of metabolic enzymes, the assumption being 
that assessment of a treated and untreated cell line will allow an effect on metabolism to be 
assessed. Measurements are highly dependent on cell numbers. The assumption is often made 
that if the metabolic activity decreases, cells must be dying. We consider simultaneous 
assessment of cell numbers, however, to be essential, as this may not be the case. 
 
Producing a soluble reaction product, MTS cytotoxicity assay is a superior alternative to the 
widely used MTT assay, in which the reaction product is water insoluble (O'Toole et al., 
2003). The MTS assay is usually used as a screen for viability of cells or rather their 
metabolic activity after treatment with compounds, though as explained above. When 
metabolites like glycoxylate or pyruvate undergo enzymatic oxidation to oxaloacetate, this is 
accompanied by reduction of NAD+ to NADH. The NADH facilitates the reduction of the 
colourless MTS tetrazolium salt, to a coloured, soluble formazan product, in the presence of 
phenazine methosulfate (PMS). The intensity of colour generation is used as a measure of the 
metabolic activity of cells, and, therefore, their viability (Malich et al., 1997; O'Toole et al., 
2003). 
 
Initial optimization of cell numbers to be used to obtain a linear calibration response curve in 
the MTS assay was necessary before proceeding with the assessment of compound toxicity. 
This was necessary in order to establish a linear correlation between cell number and the 
product produced in a specific time, to ensure the production of reliable results. For most 
tumour cells hybridomas and fibroblast cell lines, 5000 cells/well is recommended for 
proliferation studies (Promega, 2009).  
 
Subsequent to the optimization MTS assay was carried out with the various compounds at 
various concentrations and the data analyzed to assess possible selective effects on the 
premalignant, MCF10A-NeoT cell line compared to the normal MCF10A cell line. Due to 
the large number of data points and number of test compounds to be compared, the ANOVA 
test was selected. The ANOVA (analysis of variance test), unlike the students t-test, which is 
a test for the significance between two means (two-sample t-test) or between a mean and a 
hypothesized value (one-sample t-test), is a test of significant differences between multiple 
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means, assessed by comparing variances. This program requires that data (responses) are 
normally distributed (outcome is normally distributed). Like the t-test, therefore, ANOVA 
requires that data is checked for a normal distribution. This was, therefore, carried out. The 
program also requires that there is homogeneity of variance, i.e. similar variance between 
data points and hence the standard error of the means (SEM) was assessed 
(http://www.dorak.info). A normal distribution (Gaussian distribution) can be described by 
two parameters: mean () and variance (2), were  ~ N (, 2) and the distribution is 
symmetrical with mean, mode, and median, and equal at . In the special case of  = 1 and 2 
= 1, this is known as the standard normal distribution.  
A diagnostic test for the assumption of normal distribution of residuals in linear regression 
models is given by a plot of the normal probability of the residuals (difference between 
observed values of results and the corresponding fitted values predicted by regression). Each 
residual is plotted against its expected normal value. A plot that is nearly linear suggests 
normal distribution of the residuals. Such a plot was, therefore, used in the current study. 
 
All in all analysis of variance (ANOVA) is a statistical set of models that allow for different 
sources of variance between the means of several groups to be measurable. General ANOVA 
was carried out from GenStat, giving p (or F pr) values (according to the null hypothesis) to 
assess overall significant differences (see Table 3.1 below). There are three different kinds of 
ANOVA from which to choose in the GenStat software i.e. one-way, two-way and general 
ANOVA. One-way ANOVA can be used, for example, to determine the metabolic activity of 
two different cancer cell lines, where there is only one factor that could affect the metabolic 
activity of the different cell lines (Bewick et al., 2004). Once another factor is added, 
however, and for example, one of the cells were treated with three different compounds, due 
to the addition of another factor, there are now two factors in total (i.e. cell type and treatment 
compound type), and a two-way ANOVA can be used (Ekermans et al., 2010). The General 
ANOVA is, on the other hand, a general way of determining the significance effect regardless 
of the number of factors involved and was, therefore, used in this case. 
In analysing significant differences it is assumed that the treatment has induced no difference, 
i.e. that the null hypothesis is true. If the null hypothesis is true there are no differences in  the 
mean effect between the groups or treatments in the populations and, therefore, the explained 
(regression) sum of squares (ESS) (or variance estimated between groups, or the sum of 
squares (ss) divided by the degrees of freedom (df) or ms in GenStat) divided by the residual 
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sum of squares (RSS) [or variance within a group or F or variance ratio is 1]. This can be 
better explained by the formula below (Armitage and Colton, 2005): 
    
                                             
                                            
    
Where MSG = mean sum of squares between groups and MSE = mean sum of squares within 
a group. 
If the null hypothesis is not true, this will give a low significance p-value (or F pr from the 
GenStat ANOVA table, automatically generated by the GenStat programme) i.e. p<0.05. This 
indicates that the null hypothesis (Ho) should be rejected in favour of the alternative (Ha), as 
illustrated below, as there is evidence that at least one pair of means is not equal. Depending 
upon which group is compared, this was used to give information about such a group in 
relation to the other groups. 
The assumptions made in the general ANOVA used are, specifically that values are randomly 
assigned to one of “n” groups and the distribution of the means by group are normal with 
equal variances. Sample sizes between groups do not have to be equal, but large differences 
in sample sizes by group may affect the outcome of the multiple comparisons tests. This was 
not so in our experimental design and hence was the program chosen. 
The hypotheses for the comparison of independent groups are:  
Ho: u1 = u2... = uk (means of the all groups are equal) 
Ha: ui<> uj (means of the two or more groups are not equal) 
Where k is the number of groups, Ho stands for the null hypothesis statement; Ha is an 
alternative statement to the null hypothesis and u represent means of the data points 
The test performed is represented in an Analysis of Variance (ANOVA) table. This test is an 
F pr (F probability) test with N-1 degrees of freedom (df), where N is the total number of 
tests or samples. As mentioned, a low p-value or F pr value (i.e. p<0.05) indicates evidence 
to reject the null hypothesis as there is evidence that at least one pair of means are not equal 
(http://www.dorak.info).  




Table 3.1: An example of the ANOVA table from GenStat. 
Analysis of Variance for days  
Source        df          ss        ms        F        P 
Treatment  2      34.74     17.37     6.45    0.006 
Error       22      59.26      2.69 
Total       24      94.00 
 
Where df = degrees of freedom, ss = sum of squares, ms = mean sum of squares, F (also 
referred to as vr) = variance ratio and F pr (also referred to as p value) = F probability 
Formulas:            df = N-1 
 ss = 2)( xx
obs
i    
 ms =   
  
 
in this case  F =     
   
   
 2xxi 
 2iij xx 
 
Where N is the number of individual groups, x  is the mean for the entire data set, ix  is the 
mean group for i, xij is the value for individual „j‟ in group „i‟, and P value does not have any 
formula it is normally figured out from the F table (a simple comparison in this case). 
 
The ANOVA analyses the combined effect of the variables. It does not allow individual 
variables to be compared, unless a further output tests, e.g. a plot of the mean metabolic 
activity against concentration compared to the average standard error of the difference of the 
means under the general ANOVA (see Fig 3.8) or the Duncan‟s multiple range test is added.  
 
Standard error is a measure of chance variation and not actually error or mistake. Standard 
error (SE) of the mean is the standard deviation (SD) of the means in a sampling distribution 
and tells us how much variability can be expected among means. Therefore, any observed 
difference that is greater or less than the SE is a significant (significantly different) result.  
 
The Duncan‟s multiple range test was chosen from GenStat under general ANOVA to also 
better reveal the relative significance (effect) of three factors assessed on individual samples 
(i.e. compound type, concentration and replication). The Duncan‟s multiple range test was 
chosen over the t-test because it can compare multiples of variables while the t-test only 
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compares two set of variables at a time. This was carried out to closely compare the effects of 
e.g. a specific treatment at a specific concentration on different individual test samples.  
In statistics, a problem in multiple comparisons on random simultaneous experiments (Miller, 
1981) or deductions made on selected observed values (Benjamini, 2010)  arises via inference 
errors. These arise in  parameters such as confidence intervals where population parameters 
are not considered or in  hypothesis tests  where the null h ypothesis is incor rectly rejected. 
These a re mor e li kely t o oc cur when the  da ta set as a whole is considered. T echniques 
developed to prevent this, but allow significance levels for single and multiple comparisons 
to be directly compared, generally require a stronger level of evidence in order for individual 
comparisons to be considered "significant” and to compensate for the number of 
extrapolations made.  
For hypothesis testing, a problem for performing multiple comparisons is the increase in type 
I e rror that oc curs when statis tical tests are re peatedly applied. An experiment-wide 
significance lev el α, for n independent comparisons a lso termed „family wise error ra te‟ 
(FWER), is given by 
. 
is used to compensate for such error and allow a significance level to be assigned. Unless the 
tests are dependent, α increases as the number of comparisons increase. If the  comparisons 
are not assumed to be independent, then: 
 
There are dif ferent ways to assure that the FWER is at most . The  most  re liable, free o f 
independency and distribution assumptions, i s known as the Bonferroni c orrection 
. In the current study, the significant difference was assessed using 
the Duncan‟s test, which uses  such a  correction indicated by dif ferences in assigned letters 
next to the metabolic activity mean values, allowing different concentration differences to be 
assessed. If ther e a re n o c ommon letter s between two va riables that means that those  
variables are si gnificantly different. The leve l of significance in this test is based on the  
number of  tr eatments that are be ing teste d. Th e leve l of significance is  usuall y me asured 
using the following formula: 
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                                      p = 1-(1- ) p-1  
where  is the level of significance and p is the total number of treatments.  
Methods where total  never exceeds 0.05 under any conditions provide "strong" control 
against Type I error, in all conditions, including a partially correct null hypothesis. Such a 
method is the Duncan‟s multiple range test, where  P ≤ 0.05 (i.e. results are significant at 
p<0.05) (Duncan, 1955). This was chosen for the current study. 
3.3.4.1 Reagents 
 
Dulbecco‟s phosphate buffered saline (DPBS) 
A small volume of deionized water was added at room temperature to KCl (0.2 g), NaCl (8.0 
g) and KH2PO4 (0.4 g) and the MgCl2. 6H2O (100 mg) and CaCl2. 2H2O (133 mg) were 
added to the solution and mixed thoroughly before making up to a final volume of 1 L. The 
pH was adjusted to 7.35 with 1N HCl or NaOH, if necessary, and stored at 4oC. 
 
MTS in DPBS, 2:1 (mg: ml) 
MTS (30 mg) was dissolved with a magnetic stirrer in DPBS (15 ml), filter-sterilized through 
a 0.22 µm filter and stored in a dark container to prevent exposure to light. The solution was 
stored at -20oC for up to 14 days. 
 
PMS in DPBS, 0.92: 1 (mg: ml) 
Phenazime methosulfate (0.736 mg) was dissolved in DPBS (800 µl) with a magnetic stirrer. 
The solution was filter sterilized and poured into a dark autoclaved bottle. It was stored at -
20oC for up to 14 days. 
 
MTS/PMS (1: 20) 
Phenazine methosulfate solution (750 µl) was mixed with 15 ml of MTS and the solution 




Cells were cultured in a 75 Terasaki (Ti) flask, grown to 80% confluence, trypsinized (1 ml) 
and neutralized with media (2 ml). The suspension was transferred into a 5 ml Falcon tube for 
easy pipetting and 30 µl was taken to perform the cell count. The volume of the cell 
suspension was adjusted so that the cell number required for the chosen range (i.e. 1000 - 10 
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000 c ells/well) was c ontained in 100 µl for inoc ulation into e ach well of a 24 w ell ti ssue 
culture plate. When pipetting and performing counts, the suspension was mixed continuously 
to allow even distribution of cells. The cell suspensions were pipetted into the various wells 
increasing cell numbers in triplicate and repeated three times over. Subsequently each well 
was made up to 100 µl with warm media. For blanking purposes, a similar treatment series 



















Figure 3.2: The calibration curves for MCF10A (A) and MCF10-NeoT (B) optimization 
for the MTS Assay. 
 
The cells were seeded in a 96-well plate from 1000 to 10000 cells per well, and were incubated 
overnight. S ubsequently MT S/PMS solution was i ntroduced to  the wells seeded with c ells a nd 
incubated for 3 h. This was done to test the optimal reactivity of the MTS/PMS solution with the 
cells an d t hat reactivity was measured spectrophotometrically at 490 n m. T he graphs o f 
MTS/PMS r eactivity v s. s eeded n umber o f ce lls was p lotted f rom which t he linear r ange was 
identified and the points (number of cells) making up that linear range were added together and 
divided by the number of those points, which gave the optimal number of cells to be used for the 
MTS assay. 
 
The cells were allowed to adhere overnight at 37oC, 5% CO2.The PMS/MTS solution (20 µl) 
was added and the solut ion incubated (37 oC, 5% CO 2, 3 h) . The plate  was read a t 490 nm 

















subsequently plotted (absorbance at 490 nm, versus number of cells seeded), a linear range 
identified, and the optimal seeding number determined to be 4000 cells/well for both cell 
lines (Figure 3.2). 
 
After optimal numbers were established, the optimal number of cells (4000 cells/well) was 
seeded into a non-binding 96 well plate in triplicate for each treatment group. The cell 
suspension was made up to 100 µl with warm culture media and incubated at 37oC, 5% CO2 
overnight.  
 
After overnight exposure, medium was aspirated off and cells washed with HBSS and fresh 
media replaced. Cells in triplicate, were treated with 100 µl of different concentrations (4.8, 
9.5, 19, 38, 75, 150 and 300 µM) of the three prepared hypoxoside or derivative compounds 
(prepared with 0.001% DMSO in culture medium). Two controls were included i.e. medium 
and 0.001% DMSO control, to ensure that the solvent is not responsible for cell death. For 
blanking purposes and to overcome any compound-chromogen disturbances, a same series of 
treatment was prepared, but this time with no addition of cells as before. The spaces around 
the 96 well plates were filled with sterile distilled water to reduce thermal gradient and media 
evaporation. The plate was incubated overnight at 37oC, 5% CO2. After which the prepared 
PMS/MTS solution (20 µl/well) was added and incubated (37oC, 5% CO2, 3 h).  
 
The plate was read at 490 nm with a Versamax spectrophotometer and the data was plotted in 
Excel as metabolic activity (expressed as a fraction of the metabolic activity seen in the 
DMSO control, to control DMSO effects) v.s. concentrations of the various compound types. 
The data was also assessed for a parametric or non-parametric, or normal or non-normal 
distribution. The standard error of the mean (SEM) of the three replicates was also calculated 
and plotted from Excel. To assess statistical significance/variation of the metabolic activity of 
the tested cell lines after treatment with the tested compounds, a general analysis of variance 
(ANOVA) test was carried from GenStat. This test, as mentioned Section 3.2.4.1, requires 
that the data is normally distributed. Therefore, residual (SEM) plots were carried out for data 
from both cell lines (i.e. MCF10A and MCF10A-NeoT) to check the normality of the 







Figure 3.3:  Residual p lots of MCF10A (A) an d MCF10A-NeoT (B)  metabolic ac tivity 
collected data after treatment with the three hypoxoside compounds.  
 
 Plots 1-4: a histogram of residual plotted as number of tests vs. error distribution, and is roughly 
bell shaped (i.e. normally distributed); a fitted plot, plotting residuals vs. fitted values (i.e. two 
middle lines s hould b e aligned an d points w idely s pread f or a normal d istribution); plots 
residuals against expected normal quantiles (should be a straight line for a normal distribution); 
resembles plot 3except plots absolute residual values (a straight line for normal distribution).  
Histogram of residuals
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Looking at the residual plots for both cell line it was concluded that the collected metabolic 
activity data was normally distributed and the general ANOVA could be performed as it 
requirements were met. Additional output tests (i.e. post hoc tests) were also performed to 
better appreciate the MTS assay results (i.e. mean plot graphs and the Duncan‟s multiple 
range tests for both cell lines).  
3.2.5. Acridine orange/propidium iodide (PI) fluorescence microscopic assay 
 
After assessment of the effect of test compounds on metabolic activity, assessment of how 
many cells were actually dead or dying was required. There are many methods of cell death 
assessment as described in Chapter 1. Some have advantages over others. Fluorescence 
microscopy is one of the widely known methods used for cellular studies and cell viability 
assessment. Cell counts and fixed cell assays using fluorescent staining allow quantitative 
measurement of such effects (Swedlow, 2003).  
Fluorescence emissions occur when certain molecules are exposed to light of mixed or a 
specific wavelength, e.g. ultraviolet light, and emit light of a different colour and longer 
spectral wavelength. Fluorochromes, therefore, emit light of a specific longer wavelength 
(emission wavelength) when excited with light of a specific shorter wavelength (excitation 
wavelength) (Nikon, 2000-2012). Fluorescence microscopy, therefore, allows visualization of 
introduced or natural fluorescence light emitting fluorochromes within the sample prepared 
for imaging. 
This form of microscopy may involve a simple staining procedure and is relatively rapid and 
inexpensive providing fluorescence microscopes are available (Swedlow, 2003) . It also 
allows the user to view the internal details of a cell and is known for its facilitation of the 
detection of small amounts of the test material, with very high precision and sensitivity. The 
dependence on excitation and emission at a specific wavelength may be used to advantage, as 
different fluorophores of distinct excitation and emission wavelengths may be simultaneously 
viewed, as long they can be distinguished separately (Herman, 1998). 
The principle behind fluorescence microscopy is that when white light strikes the first exciter 
filter, the optimal filter, chosen for the excitation of a specific fluorophore, must allow only 
the wavelength of light required to excite the chosen fluorophore to pass through the filter. 
The next component met, is the dichroic mirror. This must reflect the required excitation 
wavelength down onto the specimen labelled with a specific fluorophore, while allowing 
59 
 
unwanted inappropriate wavelengths to pass through (Figure 3.4). Generally such dichroic 
mirrors are named or labelled according to the wavelength at which light below that specific 
wavelength is reflected, i.e. wavelength just above the required excitation wavelength 
required to excite a chosen fluorophore. Wavelengths at or below the excitation wavelength 
required are reflected and allowed to strike the specimen (Figure 3.4).  
 
Figure 3.4: Epifluorescence microscopy set up.  
 
The basic principle of fluorescence microscopy shown here is to allow excitation light through 
the exciter filter and not allow the wavelengths of light greater than that required to excite the 
selected fluorophore. The dichroic mirror reflects the light of wavelengths lower than the 
excitation wavelength of the selected fluorophore, to excite the specimen and the emitted light 
is usually greater than the excitation wavelength and will be allowed to pass through the 
dichroic mirror and through the emission filter which will only allow lower wavelengths of 
light than those emitted (Bradbury and Evennett, 1996). 
 
When the specimen with the fluorophore is excited with the correct excitation wavelength, it 
emits light of a longer wavelength than the excitation wavelength, and reflects back up 
towards the optical tube and will pass through the dichroic mirror chosen, to the eye piece or 
detector or camera (Figure 3.4). Before reaching the eye-piece or detector, or camera, the 
emitted light will further pass through the emission filter, which only passes wavelengths at 
or greater than the emission wavelength of the specific fluorophore used (Figure 3.4), 
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eliminating unwanted stray, nonspecific fluorescence. This emission subsequently passes up 
to the objective or detector camera (Lichtman and Conchello, 2005).  
Commonly used fluorochromes for imaging live and dying cells and cell nuclei under 
microscopy are AO, PI and HO, as discussed in Chapter 1. AO stains the live and dead cells 
green, HO stains both live and apoptotic cells blue and PI stains the late apoptotic and 
necrotic cells red. These dyes are usually combined, AO + PI, AO + HO and HO and PI in 
flow cytometry and for the microscopy. In the current study AO and PI were chosen as this 
combination is known to label viable (AO only) and late apoptotic (AO and PI) 
(Darizynkiewicz et al., 1992; Foglieni et al., 2001; Zamai et al., 2001). Acridine orange and 
PI fluorochromes have excitation wavelengths at 502 and 536 nm, respectively, and emission 
wavelengths at 526 and 617 nm, respectively, so were considered easily distinguishable as 
there will be no emission spectrum overlap between the two fluorochromes and were, 
therefore, chosen.  
 
In the current study, an Olympus Provis AX70 fluorescence microscope was used, and a U-
MNIB cube for AO with an excitation filter of 470-490 nm and emission barrier filter of 515 
nm. For PI the U-MWIG cube with the excitation filter of 520-550 nm and the emission filter 
of 580 nm. The dichroic mirror in these cubes for AO was 505 nm i.e. this reflects light 
wavelengths lower than 505 nm down onto the specimen and allows greater wavelengths to 
pass through (Figure 3.4). For PI the dichroic mirrors chosen reflects light wavelengths lower 
than 565 nm and allows wavelengths greater than 565 nm, through the barrier and camera 
filter (Herman, 1998; Olympus, 2012). 
3.3.5.1 Reagents 
 
Acridine orange (10 µg/ml). 
A stock solution of 1 mg/ml was prepared by dissolving 1 mg of the AO powder in 1 ml of 
warm sterile HBSS. A 1:100 dilution of the stock solution was made to produce a working 
concentration of 10 µg/ml and the solution was stored at -20oC. 
 
Propidium iodide (PI) (10 µg/ml). 
A stock solution of 1 mg/ml was made up by dissolving 1 mg of PI in 1 ml warm HBSS. The 
solution was then diluted in a 1:100 dilution factor to make it up to the concentration of the 




Acridine orange/propidium iodide (1:1) (10 µg/ml). 
The already prepared solutions of AO and PI were mixed in a 1:1 ratio before use. 
 
Moviol (10% Moviol, 23 M glycerol in 0.1 M Tris, pH 8.5) 
Moviol (2.4 g) was added to 0.2 M Tris (12 ml) covered with foil and stirred overnight, in a 
closed container. Glycerol (6 g) and dH2O (6 ml) were added to the prepared solution and 




Round cover slips (3 mm) were placed into 24 well plates and the middle of the cover slips 
pretreated with DMEM: Ham‟s F-12 complete media for ≈2 h to condition the surface of the 
cover slips, so as to assist cells to adhere. A consistent number of cells (i.e. 10 000 cells/well) 
were seeded and a suspension media made up to a final volume of 200 µl after the cells were 
allowed to adhere for ≈ 2 h and allowed to grow overnight. The next day the media with non-
adherent cells was aspirated off and cells gently washed with warm sterile HBSS. The media 
containing the hypoxoside, dimethylhypoxoside and decaacetylhypoxoside compounds (200 
µl) at different concentrations (4.8, 19, 75 and 300 µM) was carefully added to the cells and 
three controls were set out, i.e. positive control with cyclohexamine (25 µg/ml, 3 h, 37oC, 5% 
CO2), negative control with media only and 0.001% DMSO in media to check the effect of 
DMSO on cell death, as the compounds were also prepared in 0.001% DMSO. The plates 
were incubated overnight (37oC, 5% CO2), the media was aspirated off and 20 µl of AO/PI 
(1:1, 10 µg/ml) stain was added in each well for 5 min (using a modification of the method of 
Zamai et al. (2001) previously optimized for the current cell line in our laboratory, data not 
published yet). The cover slips with cells were inverted onto a rectangular glass slide 
pretreated with Moviol mounting medium (2 µl) and cells were visualized and images 
captured with an Olympus Provis AX70 fluorescence microscope (with the UMIB and 
UMWIG filter cube for AO or PI) and images were subsequently annotated and processed 
using AnalySiS v.3.0 soft imaging system software and compared for PI/AO staining. Results 
were subsequently analyzed visually and amount of fluoresce assigned from +++ to – staining 






3.3.6. Propidium iodide (PI) flow cytometric assay 
 
A flow cytometer is one of the most commonly used instruments in the tests for detection of 
apoptosis, giving information such as the ratio of apoptotic to live cells, identifying nuclear 
changes resulting from DNA cleavage, assessing viability using dyes and probes which map 
membrane dynamics and integrity (Martinez et al., 2010). Flow cytometry is a powerful 
technique used for multiple applications, from immunophenotyping to ploidy analysis, to cell 
counting and green fluorescence protein (GFP) expression analysis and detection of apoptosis 
(Luttman et al., 2006). 
 
A flow cytometer performs such analyzes by passing thousands of cells per second through 
the beam of a laser, using a flowing sheath of carrier fluid. The light that emerges as cells 
pass through allows data to be gathered and analyzed statistically by flow cytometry software 
to report cellular characteristics such as size, complexity, phenotype and health (Ormerod, 
1994).  
 
The principle behind the flow cytometer detection of fluorescently labeled cells is similar to 
that of the fluorescence microscope except the light path differs slightly (Figure 3.4 and 3.5). 
In the flow cytometer, as a cell passes through the laser beam it will refract or scatter light at 
all angles. The forward scatter (FS) or low angled light scatter is defined as that light 
scattered in the forward direction as laser lights strikes the cells and is used to analyse 
unlabeled cells. The magnitude of the FS signal is roughly proportional to the size of the cell 
and is detected by the forward scatter detector (Shapiro, 2003). The bandpass filter is always 
placed in front of the FS detector to prevent any intense laser light from reaching the detector. 
As the cell passes the band pass filter the signal generated is collected by the detector and 
translated into the voltage pulse. Small cells result in a small signal for the FS and large cells 
result in a large FS signal, therefore, the magnitude of voltage pulse recorded is proportional 
to cell size. If one plots a 1D-histogram for this data, the small cells will appear towards the 
left and the large cells towards the right. This kind of data represents only the size 







Figure 3.5: The layout of components in a flow cytometer. 
The flow cytometer is divided into 5 systems, which includes the fluidic system guiding the sample 
to the interrogation point and taking away the waste, lasers as light sources‟ for scatter and 
fluorescence assessments, the detectors which receive light and the electronics and computer system 
which convert the signals from the detectors into data and perform the necessary components 
necessary for flow cytometry analysis (adapted from Semrock, www.semrock.com/flow-
cytometry.aspx). 
 
The laser beam signal that is refracted by the cells, passing at higher angles, is called side 
scatter (SS) signal. The SS signal is generated by the granularity and structural complexity 
inside the cells. This light is focused through a lens system and collected by separate 
detectors usually situated at 90o from the laser path. The signals collected by the SS detector 
can be plotted in a 1D histogram, which then gives the complexity i.e. may reveal differences 
internal complexity of normal and damaged cell populations when represented in a scatter 
plot (Figure 3.6B, R1, R2 and R3). 
 
What appears to be one stained population in a 1D-plot in a SS histogram (Figure 3.6A) is, in 
reality, multiple of populations that can be clearly seen in a 2D plot (Figure 3.6B), giving 
more information. The peaks from the 1D-plot will correlate with a population of dots in the 






Figure 3.6: Multi-parameter flow cytometry analysis of blood cell populations.  
 
The 2D scatter plot (B) showing granularity and the size of the analyzed cells, and reveals 3 
populations, R1, R2 and R3.The 1D-histogram plot (A), shows only 2 stained populations of 
cells, the first region referred to as a negative control region (no staining region) and, thereafter, 
there is a weakly-and strongly fluorescently (FL) stained region. The 2D plot is gated to show 
only the stained populations (double headed arrow) which appear only to show only 2 populations 
in the 1D histogram. 
 
An essential feature in flow cytometry, called “gating”, allows the selective visualization of 
particles of interest (Figure 3.6), with simultaneous “removal” of unwanted particles, like 
unwanted debris from the plot (Barrett et al., 2011). In the current study, the separation of 
live and dead cells, after treatment with the prepared test compounds, was of interest. The PI 
positive (dead cells) were gated for a region, in a 1D histogram plot, and a % of events (PI 
stained cells) in that region was acquired for all test compounds at different concentrations.  
 
Another parameter that gives information on the cell function and characteristics is the 
fluorescence, which as discussed in Section 3.2.5.1, is used to describe the excitation of a 
fluorophore to higher energy levels, followed by its return to the ground state with the 
emission of light (Shapiro, 2003). The energy of the emitted light is dependent on the energy 
with which the fluorophore is excited and the specific wavelength and consequently the 
specific colour of the beam of exciting light, the parameter that determines the specificity of 
the flow cytometric assays (Ormerod, 1994). 
 
The common way of studying cellular characteristics through flow cytometry involves the 
use of added fluorophores. When the fluorophore is added to the cell sample it binds to the 
specific molecule on the cell surface or inside the cell either via histochemical affinity or 
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bound by an antibody. When a laser beam strikes the fluorophore on the cells, a fluorescence 
signal is emitted and it travels the same path as the SS (Figure 3.6B). As the light travels 
along this path it is directed through a series of filters and mirrors so that particular 
wavelength ranges are delivered to appropriate detectors in a manner similar to that desired 
for fluorescence microscopy (Section 3.2.5.1). This is achieved using a series of filters, i.e. 
excitation, dichroic mirror and emission or barrier filter, for fluorophores with increasingly 
lower wavelength detection (Luttman et al., 2006) (Figure 3.5). 
 
In a population of labelled cells some will be brighter than the others. As each cell passes 
through a laser, a fluorescence signal is generated and fluorescence light is then directed to 
the appropriate detector which is translated into a voltage pulse proportional to the amount of 
fluorescence emitted and all the voltage pulses are recorded and can be presented graphically 
in a histogram plot (Figure 3.6) (Shapiro, 2003). A two fluorophore experiment can be 
performed, but the two fluorophores must have emission peaks far enough apart, so that 
separated emission signals can be collected.  
For the current study the Beckman Coulter Epics XL Flow Cytometer was used. This has the 
capability to analyse up to 4 colours of immunofluorescence from a single air-cooled laser. 
This machine uses a detector range of 300 nm - 800 nm, with a maximum analysis rate of 
>3300 cells/sec, and a minimum cell size of <0.5 µm. The fluorophore used in the current 
study was propidium iodide which is popular for the detection of cell death and is cheap. The 
method chosen was a previously optimized method of Zamai et al. (2001). The results were 
subsequently checked using the trypan blue method of detecting cell death and total counts, 
allowing estimate of % cell death to be calculated and increases or decreases in cell 
proliferation to be monitored. 
3.3.6.1 Reagents 
 
Propidium iodide (50 µg/ml) 
A stock solution (1 mg/ml) was prepared by allowing 1 mg of PI to dissolve in 1 ml of warm 
sterile HBSS. The solution was diluted 1:20 in HBSS to give 50 µg/ml working concentration 








A consistent number (i.e. ≈ 200 000 cells/flask) of cells was seeded into 25 Ti flasks and 
incubated (37oC, 5% CO2) overnight to allow cells to adhere and grow. The following day the 
media with non-adherent cells was removed and the cells washed gently with HBSS. The 
media containing the three test compounds at different concentrations (150 and 300 µM for 
HYP and 4.8, 19, 75 and 300 µM for DMH and DAH) (2 ml/flask/concentration) was added 
to the cells. Three controls were set out as in AO/PI staining protocol. The cells were 
incubated or treated overnight with the test compounds. The flask contents were decanted 
into respective 15 ml Falcon tubes with media. The adhered cells left in the flasks were 
trypsinized with 1 ml trypsin-EDTA and neutralized with the decanted media containing dead 
and floating cells. The cells were gently mixed and 500 µl withdrawn into a 5 ml culture tube 
for flow cytometric analysis and 15 µl placed into a 1.5 ml Eppendorf tube for the addition of 
trypan blue and counting in a hemocytometer chamber.  
 
Propidium iodide (10 µl) was added into the culture tube for flow cytometric analysis, 
vortexed gently and incubated at room temperature in a dark area for 15 minutes. Cell 
viability was subsequently analyzed, within an hour, using a flow cytometer.  
 
The flow analysis was carried out using an Epics XL flow cytometer (Beckman Coulter) 
equipped with a 488 nm Argon laser. The FSC and SSC fluorescence intensities were 
collected using a log scale, while the PI intensity (red dye) was collected with a linear scale. 
The emission filter used was 620 nm for PI. The medium flow rate used to analyze the tested 
cells was sufficient to ensure a minimum of 5000 counts per tested sample. Assessment of 
cytotoxicity was carried in triplicates and twice over, i.e. n=2. 
3.3.7. Trypan blue hemocytometric assay 
 
Use of the Improved Neubauer hemocytometer chamber is common and widely used for 
counting cells. This is because it provides a cheap and simple method for counting cells. For 
detection of cell death this method of counting cells is usually coupled with staining of cells 
with trypan blue dye, a dye that stains the nucleus of cells with damaged membranes, i.e. 
dead cells or late apoptotic or necrotic cells (van Dooren et al., 2004). The cell membrane is 
naturally intact, but when the cell dies it is disrupted and allows bigger molecules to go 















Figure 3.7: Improved Neubauer Hemocytometer counting chamber grid lines.   
The grid lines of the large squares of the hemocytometer define one millimeter and the depth of 
the chamber is 0.1 mm allowing counts of cells per ml to be calculated (Dacie and Lewis, 
1970). 
 
A hemocytometer is a glass chamber, engraved with calibrated squares and with raised sides 
that will hold a coverslip at 0.1 mm above the chamber floor. The total volume of one large 
square is 0.0001 ml. The hemocytometer is filled with the cell suspension, containing 
uniformly dispersed cells for counting, by placing the pipette with the cell suspension at the 
edge of the hemocytometer and expelling the fluid slowly, so that the suspension is drawn 
uniformly into the chamber by capillary action.  
 
There are two methods of counting cells from the hemocytometer chamber. The first one 
involves counting cells from the four outer big squares and calculating cell number using the 
equation and is used when cells are large and not too numerous:  
 
cells per ml = total cells counted x 2500 x dilution factor. 
 
The second method involves counting five squares in the middle block and calculating the 
cell number using the equation: 
 




The choice of method depends on the cell concentration and the accuracy depends on the 
number of squares counted cells. This method was not anticipated to be as accurate as flow 
cytometry but it was required to give an idea of the effect of tested compounds on cell 
number and approximate number of dead cells in such total cell populations.  
3.3.7.1 Reagents 
 
Trypan blue (0.4%) 
Trypan blue (40 mg) was dissolved in 10 ml HBSS, and was freshly prepared for use. 
3.3.7.2 Procedure 
 
The cells discussed in Section 3.2.6.3 were mixed with the 0.4% Trypan blue in a 1:1 ratio. 
The cells were mixed with a micropipette to prevent clumping and 30 µl was introduced into 
both chambers of a prepared hemocytometer and placed on an inverted light microscope and 
the cells in four large squares were counted in both chambers, counting both live and dead 
cells (i.e. 8 x 1 cm grid squares), twice in duplicate. The following equation was used to 
calculate the total number of cells (averaged over 8 grid squares): 
 
Total number of cells = total number of counted cells x 10 000 
                                                            8 
 = cells/ml 
 
The average total number of cells, both dead (blue stained) and live (not stained), was 
counted and averaged over at least two replicate repeat experiments and plotted as an 
additive/stacked column graph against the different concentrations of the different 
compounds, to reflect the effect of treatment and concentration on the cell numbers of normal 
and abnormal cell lines. A second graph was plotted as an un-stacked column plot, plotting 
the % cell death within each treatment group, corrected for (minus) the cell death induced by 











3.4 RESULTS AND DISCUSSION 
3.4.1 The effect of hypoxoside, dimethylhypoxoside and decaacetylhypoxoside effect on 
the metabolic activity of MCF-10A and MCF-10A-NeoT cell lines. 
 
All the hypoxoside test compounds (i.e. HYP, DMH and DAH) share a common core 
structure but differ in the methoxy substituents on the benzene rings and on the glucose 
moieties. The MTS assay was carried out to provide initial indications of the effect of the 
hypoxoside and its derivatives on the normal human epithelial cell line (MCF-10A) and 
premalignant human epithelial cell line (MCF-10A-NeoT).  
 
The data from the MTS assay, for both the MCF10A and MCF10A-NeoT cell lines, was 
found to be normally distributed, according to the residual plots of normality from GenStat 
(Figure 3.3) and the SEMs calculated and recorded as error bars in Figure 3.8 seem to show 
no major variance within replicates. Since this was the case, and the data showed a normal 
distribution, the parametric test known as a general analysis of variance (ANOVA) could be 
used to explore any significance difference in results, both in terms of the overall treatment 
(compound type) as well as the overall effect of concentration within and between compound 
types. This was assessed by comparing the averaged effect using the mean plot of the mean 
metabolic activity and significant differences of all the factors (compound type, concentration 
and replication) using the most informative Duncan‟s analysis.  
 
Inspection of the MTS results (Figure 3.8A, expressed as a fraction of the DMSO control) 
seems to indicate that the DAH has the most significant effect on the MCF10A cells with the 
DMH partially stimulating metabolic activity, especially at 38 µM and depressing activity at 
300 µM. The DAH seems to depress activity almost to the same degree from a concentration 
of 9.5 µM, but not significantly, and the HYP seems to have little effect over all 
concentrations. All compounds seem well tolerated, though effects of various compounds do 
seem to differ slightly. At this stage how significant these results and differences were, was 
not yet calculated. 
 
Similar trends seem evident in the MCF10A-NeoT cells (Figure 3.8B) with HYP and DMH 
seemingly stimulating cell metabolism at concentrations 4.8-38 µM, but the DAH apparently 
significantly depressed activity, especially from a concentration of 19-300 µM (Figure 3.8B). 
Once again the significances of these differences between compound groups and different 






Figure 3. 8: M TS assay metabolic ac tivity results of M CF10A and M CF10A-NeoT 
treated with three hypoxoside compounds.  
The cells were seeded an d allo wed to  ad here overnight, treated with t hree d ifferent 
compounds (i.e. HYP, DMH and DAH) at different working concentrations (i.e. 4.8-300 µM) 
in tr iplicate, and allo wed to  s tand o vernight. The tetrazolium salt, MT S was in troduced an d 
conversion to soluble formazan (for 3 h) and was analyzed spectrophotometrically at 490 nm 
on tests repeated 3 times and averaged. The effect of hypoxoside derivatives on the metabolic 
activity of the MCF10A cell line (A) and on the MCF10A-NeoT cell line (B), expressed as a 
fraction of the DMSO control to ensure effects were due to drugs and not diluting solvent were 
plotted u sing a bar g raph a nd s tandard er ror o f th e mean ( error ba rs, SEM), for n=3 and 
significance as sessed u sing t he ANOVA. NOTE: A s ea ch b atch o r s amples were run at 
different times and DM SO and media controls v aried s lightly, t he same symbol as th e 



















































Table 3.2: Analysis of variance (ANOVA) table from GenStat. 
Variate: Metabolic activity 
MCF10As 
Source of variation df s.s. m.s. v.r. F pr. 
Replication stratum 2  0.017518  0.008759  1.18  
 
Replication.*Units* stratum 
Compound_type 2  0.182297  0.091149  12.24 <.001 
Concentration 8  0.063772  0.007971  1.07  0.398 
Compound_type.Concentration  
 16  0.090376  0.005649  0.76  0.722 
Residual 52  0.387319  0.007448   
 
Total 80  0.741282 
 
MCF10A-NeoTs 
Source of variation df s.s. m.s. v.r. F pr. 
 
Replication stratum 2  1.418709  0.709355  152.18  
 
Replication.*Units* stratum 
Compound_type 2  0.149490  0.074745  16.04 <.001 
Concentration 8  0.190566  0.023821  5.11 <.001 
Compound_type.Concentration  
 16  0.133313  0.008332  1.79  0.059 
Residual 52  0.242383  0.004661   
 
Total 80  2.134462    
 
The general ANOVA analysis of the MTS results (Table 3.2, compound type), confirmed that 
compound type (i.e. HYP, DMH and DAH) had an overall significantly different effect on 
the metabolic activity of the MCF10A cells, as the p value (F pr) calculated was <0.001 
(where "p<0.05" is the probability of this being so by chance at less than 5 percent). By 
visual inspection of graphical data in Figure 3.8A, this would seem to be true. It would seem 
that the DAH decreased the metabolic activity of the MCF10A cells relative to the control 
(Figure 3.8A), with HYP and finally DMH having lesser effects (Figure 3.8A). A similar 
effect is seen in the MCF10A-NeoT cell line (Figure 3.8 B) for the DAH and it appeared to 
be concentration-dependent for the range tested. Here the general ANOVA test confirmed 
visual inspection interpretation of graphical data by delivering an overall significant p value 
of p<0.001 for compound type (Table 3.2, compound type) supporting the rejection of the 




Though it would seem from Fig. 3.8B, by visual inspection, that the DAH decreases the 
metabolic activity of the MCF10A-NeoT cells most, followed by the HYP and finally DMH 
(Figure 3.8B) i.e. this gave a similar trend for compound type, as seen in the MCF10A cells 
(Figure 3.8A), to assess such an effect on individual test concentrations within the group, 
relative to each other the Duncan‟s and mean plot (Figure 3.9) needed to be carried out. This 
was carried out after the general assessment on the effect of concentration on the test groups. 
 
The average effect of changing concentration of the different compounds, on each individual 
cell line, explored using the ANOVA, showed no concentration-dependent significantly 
different effect on the metabolic activity of the MCF10A cells (giving a p value of p = 0.398, 
i.e. an effect which would seem less significant, according to the p value, than the effect 
induced by the compound type, which gave a p value of p<0.001) (Table 3.2, concentration). 
The general effect of concentration on the MCF10A-NeoT cells appears significant (p<0.001 
compared to p 0.398 for MCF10A cells), confirming what is visually seen (Figure 3.8A vs. 
B). Though the DAH did give a depression of activity, this depression on the metabolic 
activity of the MCF10A cells was similar, though more slight and less concentration-
dependent, over a large range of concentrations (Figure 3.8A), unlike the increasing effect 
with increasing concentration on the MCF10A-NeoT cells (Figure 3.8B).  
 
By visual inspection, the concentration producing the greatest effect on the MCF10A-NeoT 
cell line seems to be the 300 µM concentration of the DAH compound, i.e. this concentration 
significantly decreased the metabolic activity of the MCF10A-NeoT cell line compared to all 
concentrations of other compounds (Figure 3.8B). The ANOVA does not distinguish such an 
effect specifically as individual compound concentrations are analyzed within each 
compound type (Table 3.2, concentration) and not individual concentrations in each group in 
relation to each other individually. Therefore, a statistical package comparing individual 
concentrations within the group, e.g. the Duncan‟s comparison, was still required at this 
stage.  
 
The results from the general ANOVA for the combined effect of concentration and the 
compound type for both MCF10A and MCF10A-NeoT (Table 3.2, compound 
type.concentration) were found to be p=0.722 and p=0.0593 (Figure 3.8A and B, 
respectively). As "p<0.05" this means that there was no significantly different effect on the 
MCF10A but an almost significant effect on the MCF10A-NeoT cell line using the 5% level 
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of discrimination i.e. the concentrations change and compound type produced similar trends 
in the MCF10A and MCF10A-NeoT cells metabolic activity, though this effect only just 
missed being significant overall by 0.093 (just greater than 0.05) for the MCF10A-NeoT cell 
line (Figure 3.8B). This is possibly because, when results of treatment type and concentration 
are considered as a group for the MCF10A and MCF10A-NeoT, differences in one treatment 
relative to the other treatment on each cell type may be obscured when being considered as 
part of the group. 
 
Plots of the means of the metabolic activity against concentration of HYP, DMH and DAH 
were, therefore, plotted using GenStat, under general ANOVA, as a further output. This was 
done to facilitate the assessment of the effect of both treatment type and concentration on 
individual samples in either MCF10A or MFC10A-NeoT, and to assist in revealing 
significant differences not seen in general ANOVA analysis data (all values lying outside the 
av. SED being significant).  
 
These graphs show the distribution of the collected data means and the distribution of points 
plot when the concentration of the three compounds (HYP, DMH and DAH) was altered (Fig 
3.9). Such plots show the metabolic activity on the y axis and concentration of the various 
compounds on the x axis, and the various data points representing the various compounds 
plotted with differently coloured data points for both MCF10As and MCF10A-NeoTs 
(indicated by Fig 3.9 A and B, respectively).  
 
The average standard error bar indicates the predicted values of the standard error of the 
section for the plotted graph (Figure 3.9). This plot of the means shows that the DAH 
derivative seems to depress the metabolism of MCF10A-NeoT cells in a more concentration-
dependent manner than seen on the MCF10A cell line (Figure 3.9 B vs. A), with a depression 
in metabolic activity being significant over the 9.5-300 µM range for the MCF10A-NeoT 
cells. The 150 and 4.8 µM level of DAH induced less significant results on the MCF10A 
cells (Figure 3.9A), with lower metabolic activity values being induced in the MCF10A-
NeoT cells, though trends were similar for the MCF10A cells. The 150 µM and 300 µM 
concentrations of DAH showed a marked effect on the MCF10A-NeoT cells, however, with 








































Figure 3.9: Mean plot of the mean metabolic activity induced by various concentrations 
(µM) of compounds tested on the MCF10A and MCF10A-NeoT.  
 Mean plot of the metabolic activity (Y axis) of the two cell lines MCF10A (A) and MCF10A-
NeoT ( B) after treatment with th e three test  co mpounds (i.e. HYP - hypoxoside, D MH- 
dimethylhypoxoside and D AH- decaacetylhypoxoside) at d ifferent concentrations (X ax is). 
The av erage s tandard error of t he difference (av.SED) bar in dicates t hat the concentration 
points outside of the bar are outside of the p redicted er ror and, therefore, ha ve a significant 
effect o n the cells from th ose concentration p oints inside th e b ar. Med = medium co ntrol, 
DMSO = dimethyl s ulfoxide. NOTE: As each b atch o r samples were run at different t imes 
and DMSO and media controls varied slightly, the same symbol as the compound type is used 
for the controls.  
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Visual inspection of the metabolic activity of the MCF10A-NeoT cell line, displayed as a bar 
graph plot, like the mean metabolic activity plot, seems also to suggest that the metabolic 
activity was decreased to a greater extent in the MCF10A-NeoT cell line than the activity of 
the MCF10A cells after treatment with DAH (Figure 3.8, compared to 3.9A and B).  
 
As mentioned, the DMH on the other hand, seems to stimulate the metabolic activity of 
MCF10A, most significantly at 38 µM (Figure 3.8A and 3.9A), but also at most levels below 
this value, though not at 75-300 µM. A similar effect is seen in the MCF10A-NeoT cells at 
levels below 75 µM (Figure 3.8, 3.9B). The HYP seems to have little effect on the MCF10A 
cells (except at 300 µM) with the DAH depressing metabolic activity of MCF10A cell line 
significantly from the 9.5 µM to 300 µM range (Figure 3.9A) (though strangely not 
significantly at 150 µM (Figure 3.8A, 3.9A). At this stage, however, the question remained as 
to whether all such effects are significantly different with respect to one another as a measure 
of such significance was still lacking. 
 
Looking at the overall effect of the three compounds on the MCF10A, as represented in the 
plot of the means, however, except for the DAH compound and DMH, the HYP compound 
does not seem to have significant effect in depressing metabolic activity over the test range 
(as most points fall in the range of the average SED bar i.e. not a very wide range of around 
0.2-0.55) (Figure 3.9A). Some increase in metabolic activity, however, in both cell lines was, 
to some extent, seen in the case of HYP and DMH treatments (Fig 3.9A and B). The 
concentration of DAH, however, seems less important for depressing metabolic activity (of 
the MCF10A cells) than its intrinsic nature of the compound (Fig. 3.9 all values outside of av. 
SED). A program assessing and measuring relative effects of various concentrations would 
more directly indicate which concentrations cause the most significantly different and 
important effect, however.  
In summary, looking at the effect of the three compounds on the premalignant MCF10A-
NeoT cell line, the mean plot from GenStat, confirms that the DAH derivative has the more 
marked effect, markedly reducing the metabolic activity (Fig 3.8 and Table 3.2). This is 
validated by points outside the average standard error of the difference range bar plot (av. 
SED) in the plot of the mean. This indicates a major depression of the metabolic activity 
between 150 and 300 µM, in a range of 0.05-0.4 (Figure 3.9B), a very wide range of values. 
This indicates significant differences between different compounds, of different 
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concentrations, on the metabolic activity of MCF10A-NeoT cells. In the premalignant cell 
line (i.e. MCF10A-NeoT cells), the DAH compound seems have the most significant, 
selective metabolic effect, though the metabolic activity of the MCF10A cells is slightly 
affected. Therefore, the DAH compound may have possible applications as an anti-cancer 
drug and effects should be further explored.  
After rejection of the null hypothesis, i.e. the statement that the treatments have no significant 
effect, and to check which results were significantly different relative to one another, both 
within specific treatment groups and between such groups, a multiple comparison test (or 
further post hoc test), was performed. This was completed to further expand the conclusions 
from the mean metabolic activity plot (Figure 3.9). Though there are a number of programs 
facilitating specialized multiple comparisons, the Duncan‟s multiple range test was chosen as 
it allows closer and more direct and accurate comparison of variables such as the effects of 
concentration and compound type. The mean plot (Figure 3.9) and the plot of the metabolic 
activity against metabolic activity (Figure 3.8), however, are necessary as the Duncan‟s gives 
no indication of whether the effects of compound type and concentration have stimulatory or 
depressing effects on metabolism. 
 
As mentioned, the Duncan‟s multiparameter test is an analytical program for testing 
significant difference indicated by the assignment of a distinct letter to significantly different 
metabolic activity values. Looking at the effect of the three compound types on the metabolic 
activity, according to the Duncan‟s analysis, it is observed that all compound types affect the 
metabolic activity of the MCF10A cells significantly differently relative to one another, 
(Table 3.3, MCF10A compound type, indicated by “a”, “b”, “c” letters assigned for DAH, 
HYP and DMH, respectively). This confirms what is apparent from the graphical 
representation of the MTS values (Figure 3.8A).  
 
When considering the effect of compound type alone, the metabolic activity of the MCF10A-
NeoT cells it is seen to be not significantly different when treated with the HYP and DMH 
(Table 3.3, MCF10A-NeoT, Compound type, both being represented by “b”). The metabolic 
activity of the premalignant cells, after treatment with these two compounds are not 
significantly different to each other but significantly different from the metabolic effects 
induced by DAH compound (Table 3.3, MCF10A-NeoT compound type, DAH, HYP and 
DMH being assigned the letters “a”, “b”, “b”, respectively). Analysis of this parameter alone 




The analysis of the overall effect of concentration only on the two test cell lines showed that 
of all concentrations, only the 300 M concentration had a significant effect on the MCF10A 
cell line relative to the DMSO control (Table 3.3, MCF10A, concentration, 300 M 
represented by “a” and the DMSO control by “b”). For the MCF10A-NeoT cell line both the 
150 and 300 M concentrations had a significant effect relative to the DMSO control (Table 
3.3, MCF10A-NeoT, concentration, 300 and 150 M represented by “a” and “ab”, 
respectively, while the DMSO control was represented by “cd”). 
 
From the final multiparameter Duncan‟s analysis for both compound type and concentration, 
where the MCF10A-NeoT cells shows the greatest depression of the metabolic activity at 300 
µM DAH with a gradual decrease in concentration-dependent depression from 150, 75, 38 – 
19 µM DAH in metabolic plots (Figure 3.8B), the effects 300 and 150 µM DAH seem most 
significantly different from the DMSO control (Table 3.3, MCF10A-NeoT, Compound 
type.concentration, 300 and 150 µM DAH are represented by an “a” and “ab”, whereas the 
DMSO control is represented by “cdef”). Though the 150 µM DAH concentration produces 
results not significantly different to those of the 38, 75, 300 µM DAH (Table 3.3, MCF10A-
NeoT, compound type.concentration, the 150 µM concentration represented by “ab”, and the 
38, 75, 300 µM DAH represented by “bcd”, “bc” and “a”), results were significantly different 
to the 300 µM HYP and 19 µM DAH treatments (Table 3.3, MCF10A-NeoT, Compound 
type.concentration, the 300 µM HYP and 19 µM DAH concentrations both represented by 
“cde”). The 300 µM HYP and 19 µM DAH concentrations, in turn, however, were not 
significantly different from the DMSO control (Table 3.3, MCF10A-NeoT, compound 
type.concentration, the DMSO control represented by “cdef”). Therefore, only the 300 and 
150 µM DAH produced significantly different effects on the MCF10A-NeoT, compared to 
the DMSO control (Table 3.3, MCF10A-NeoT, Compound type.concentration, 300 and 150 
µM DAH giving “a” and “ab”, whereas the DMSO control is represented by “cdef”).  
 
This appears to mean that, though the effect of the 150 µM DAH is not significantly different 
from the 300 µM DAH effect on the MCF10A-NeoT, for drug choice, the 300 and 150 µM 
DAH concentration should be chosen over lower concentrations as the lower concentrations 
of DAH and the 300 µM HYP would not be effective choices as they produce results not 




Though from the ANOVA readout for the effect of concentration (Table 3.3, MCF10A-
NeoT, Concentration), concentration differences seem not as important as the effect of 
compound type in the case of the MCF10A-NeoT cells (Table 3.3 MCF10A-NeoT, 
concentration, most giving similar not significantly different results), DAH would possibly be 
the compound of choice and 300 µM or 150 µM the level of choice for treatment of a 
premalignant breast epithelial cell mass, of a similar phenotype to that represented by the 
current premalignant breast cancer model used in this study. The selection of either 
concentration of DAH, however, probably depends on what concentration is best tolerated by 
the “normal” MCF10A cell line.  
 
On the MCF10A cells, though the 300 µM DAH compound seems visually to have a 
significantly different effect relative to the other two compounds and the DMSO control 
(Figure 3.8A and 3.9A). The Duncan‟s evaluation of the effect of concentration and 
compound type showed that the 300 µM concentration of DAH had no significant effect in 
decreasing the metabolic activity of the MCF10A cell line relative to the DMSO control 
(Table 3.3, MCF10A, Compound type.concentration, revealed by ”a” and ”abcdef” for 300 
µM DAH and DMSO control, respectively). This was also true for any other compound types 
except the 150, 9.5, 19 and 38 µM DMH concentrations (Table 3.3, MCF10A, Compound 
type.concentration all other compound types giving ”a” and a combination of other letters, 
whereas the DMH concentrations had no ”a” and the DMSO control, ”abcdef”). In the 
MCF10A cells most concentrations of DMH, except the 300 µM concentration, produced a 
significantly different effect from the 300 µM DAH, as is evident from inspection of Figure 
3.8A. The DMH compound seems to stimulate metabolic activity over most concentrations, 
relative to other compounds, whereas the 300 µM DAH has an overall depressing effect on 
metabolism (Figure 3.8A). This difference was shown to be not a significant result, however, 
as the various DMH concentrations do not produce an effect significantly different from the 
DMSO control (Table 3.3, MCF10A, Compound_type.concentration, the DMSO control 
represented by “cdef” and “abcdef” and various DMH concentrations being represented by a 
combination of these letters). This means that essentially all levels of test compounds were 
well tolerated by the MCF10A cells, as the Duncan‟s analysis becomes more reliable when 
more parameters are included. The results seen when considering only concentration effects, 
i.e. that the 300 µM concentrations had significant effect may, therefore, be disregarded (i.e. 
results from Table 3.3 concentration, where 300 µM concentrations are assigned an “a” and 
the DMSO control “b”). This means the DAH shows overall selective cytotoxicity for the 
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MCF10A-NeoT relative to the MCF10A cells and is possibly the overall drug of choice as, 
for the treatment of Ras related premalignant breast cancer, no compound really emerges as 
having a greater effect than the 150 and 300 µM level of DAH according to the MTS assay.  
 
At this stage, however, the question remains: is the MTS assay monitoring metabolic activity 
related to cell death and increased or decreased proliferation? To address these questions 
further staining and flow cytometry methods for assessing viability and confirmatory total 




Table 3.3: Duncan's multiple range test. 
MCF10A (controls in boxes) 
Compound type 
  Mean  
DAH  0.3051  a    * 
HYP  0.3562  b    * 
DMH  0.4210  c    * 
 
Concentration 
   Mean 
 300 µM  0.2899  a * 
 75 µM  0.3469  ab 
 150 µM  0.3568  ab 
 Med contrl  0.3629  ab 
 9.5 µM  0.3674  ab Not significantly different from a*, b* and to each other 
 19 µM  0.3725  ab 
 38 µM  0.3776  ab 
 4.8 µM  0.3812  ab 
DMSO contrl  0.3918  b * 
 
Compound_type.Concentration  
                                              Mean  
DAH 300 µM 0.2343  a  *  
DAH 38 µM 0.2489  ab   
DAH 9.5 µM 0.2664 abc   
DAH 19 µM 0.2796  abcd   
DAH 75 µM 0.2915  abcde      significantly different to f* but not to each other 
HYP 300 µM 0.2993  abcde   
HYP 150 µM 0.3202  abcde    
DAH 150 µM 0.3324  abcde   
DMH 300 µM 0.3360  abcde   
DAH Med contrl 0.3484  abcdef 
HYP Med contrl 0.3570  abcdef 
HYP 38 µM 0.3660  abcdef  not significantly different to a* and to each other 
HYP DMSO contrl 0.3671 abcdef  
HYP 4.8 µM 0.3671  abcdef 
DAH 4.8 µM 0.3693  abcdef  
HYP 75 µM 0.3713  abcdef   
HYP 19 µM 0.3741  abcdef 
DAH DMSO contrl 0.3753 abcdef  
DMH 75 µM 0.3780  abcdef 
DMH Med contrl 0.3833  abcdef  
HYP 9.5 µM 0.3836  abcdef 
DMH 4.8 µM 0.4073  abcdef 
DMH 150 µM 0.4177  bcdef significantly different to a* but not to the values on the bracket above  
   and below 
DMH DMSO contrl 0.4330  cdef      
DMH 9.5 µM 0.4523  def     significantly different to a* and ab but not to each other 
DMH 19 µM 0.4640  ef    also significantly different to abc 




MCF10A-NeoT (controls in boxes) 
Compound_type   
 Mean  
DAH  0.2470  a *  
HYP  0.3163  b                  significantly different to a* but not to each other 
DMH  0.3502  b    
 
Concentration 
  Mean  
 300 µM  0.2022  a * 
 150 µM  0.2523  ab * 
 75 µM  0.2809 bc * 
 Med contrl  0.3020 bcd    significantly different to a* but not to each other 
 38 µM  0.3162 bcd    
 19 µM  0.3413  cd  
 DMSO contrl  0.3416  cd    significantly different to a* and ab* but not to each other 
 4.8 µM  0.3485  cd    
 9.5 µM  0.3556  d   *  
 
Compound_type.Concentration 
  Mean  
 DAH 300 µM  0.0472  a   * 
 DAH 150 µM  0.1256  ab  *  
 DAH 75 µM  0.2262 bc   *         significantly different to ef*** and f*** but not to each other 
 DAH 38 µM  0.2351 bcd *  significantly different to a* and f* but not to each other 
 DAH 19 µM  0.2629  cde     
 HYP 300 µM  0.2652  cde    
 DAH Med Contrl  0.2745  cdef    
 HYP Med Contrl  0.2836  cdef    
 DMH 300 µM  0.2941  cdef    
 DMH 75 µM  0.3050  cdef    
 HYP DMSO contrl  0.3066  cdef    
 HYP 75 µM  0.3115  cdef    
 HYP 150 µM  0.3121  cdef    
 DMH 150 µM  0.3194  cdef    
 HYP 9.5 µM  0.3243  cdef    significantly different to a*and ab* but not 
       to each other  
 HYP 4.8 µM  0.3260  cdef    
 DAH 9.5 µM  0.3390  cdef     
 DMH Med Contrl  0.3479  cdef     
 DAH 4.8 µM  0.3495  cdef     
 HYP 38 µM  0.3510  cdef     
DMH DMSO contrl  0.3552  cdef      
 DMH 38 µM  0.3625  cdef     
DAH DMSO contrl  0.3631  cdef     
 HYP 19 µM  0.3664  def     
 DMH 4.8 µM  0.3698  def                        significantly different to a*, ab* and bc  
                                 but not to each other 
 DMH 19 µM  0.3947  ef   *** 
 DMH 9.5 µM 0.4035 f     *** 
82 
 
3.4.2 The influence of hypoxoside and its derivatives on cell death of MCF-10A and 
MCF-10A-NeoT cell lines using AO/PI staining 
 
The fluorescence microscopy results of AO (cells staining green and indicating all cells) and 
PI staining performed for the assessment of induction of apoptosis or cell death (those stained 
red revealing dead and dying cells) in normal and premalignant cells are summarized in Table 
3.4 below. 
 
Table 3.4: Cell death indicated by PI staining in the two cell lines seen after treatment 


















cell death rate 
Concentration 
(µM) 10 A NT 
DMSO Control - - 
Media Control - - 














































































Figure 3.10: Effect of various concentrations of hypoxoside and its derivatives on 
MCF-10A assessed using AO/PI staining. 
  
The MCF10A cells were treated with the three compounds overnight and then treated with 
acridine orange and p ropidium iodide. The effect of t he co mpounds was analysed w ith 
fluorescence microscopy. T he AO stained v iable cells g reen and P I s tained d ead ce lls red. 
(A) AO/PI s taining with th ree d ifferent compounds tr eated M CF10A ce lls. ( B) A O/PI 
staining with cyclohexamide, 0.001% DMSO and medium treated MCF10A cells and these 











3.4.2.2 Cell death assessment of MCF10A-NeoT cell line through AO/PI staining 
 
 
Figure 3.11: Effect of various concentrations of hypoxoside and its derivatives on 
MCF10A-NeoT assessed using AO/PI staining.  
The MCF10A-NeoT cells were treated with the three compounds overnight and then treated with 
a 1:1 mixture of acridine orange and propidium iodide. The effect of the compounds was analysed 
with fluorescence microscopy. The AO stained viable cells green and P I s tained dead cells red. 
(A) AO/PI s taining with t hree d ifferent compounds tr eated MCF 10A-NeoT ce lls. ( B) A O/PI 
staining with cyclohexamide, 0.001% DMSO and medium treated MCF10A-NeoT cells and these 






The staining technique used, optimized specifically for the use with the current cell lines, 
seems to indicate selective induction of cell death in the MCF10A-NeoT (NT) cells by all 
compounds (Table 3.3 and Figure 3.10 and 3.11). This only partially seems to agree with the 
Duncan‟s analysis (Table 3.3). 
As mentioned earlier, AO binds to DNA and RNA in both living and dead cells and PI binds 
DNA and RNA but is excluded from viable cells. AO staining, therefore, indicates the total 
number of cells present and PI staining indicates that in these cells there is no significant 
induction of cell death in the normal control MCF10A (10A) cell line, except at a 300 µM 
DAH (Figure 3.10A). This agrees with the Duncan‟s analysis and appears to indicate that the 
DAH, HYP and DMH compounds are not toxic to the normal control MCF10A cells at all of 
the test concentrations. The amount of cell death induced by the highest concentration of 
DAH was slight and not as significant as that of the positive control (cyclohexamine) (Figure 
3.10) and all levels of DAH were similarly well tolerated. This seems to agree with the plots 
of the MTS and mean metabolic activity (Figure 3.8 and 3.9) and possibly indicates that the 
DAH and all other compounds are well tolerated by the normal breast epithelial cells 
(assessed using the MCF10A cell line). 
The stained premalignant (MCF10A-NeoT) cell line samples, on the other hand, appeared to 
show cell death from even the lowest concentration of HYP (Figure 3.11A). Significant 
induction of cell death indicated by bright red staining of the cells seems to start at a 
concentration of 4.8 µM HYP and DAH, and at 38 µM DMH (Figure 3.11A), a result not 
well reflected in the HYP and only vaguely reflected in DMH and DAH, in the MTS results 
(Figure 3.8, 3.9 and Table 3.3 of the Duncan‟s multiple range test).  
The control MCF10A cells show positive induction of cell death with cyclohexamide 
treatment whereas the DMSO-treated cells do not show significant staining, indicating that 
staining seems to accurately reflect the non-viability and viability of cells, respectively 
(Figure 3.10B). The MCF10A-NeoT cells seem to exhibit some resistance to induction of cell 
death with cyclohexamide treatment (the positive control) (Figure 3.11B). Propidium iodide 
staining, however, seems to indicate that the test system accurately reflects the presence of 
live and dead cells in the MCF10A-NeoT cells also and that all compounds show selective 
activity against the ras transfected premalignant cell line (Figure 3.11A). To resolve slight 
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discrepancies in the toxicity levels indicated by the MTS and staining assays, flow cytometry 
checks using PI staining and cell counts were performed. 
It should be noted, at this stage that possibly the staining results may most accurately reflect 
cell death as the MTS assay may give a result more susceptible to error from the changes in 
cell number (as the MTS assay is highly susceptible to such influences). In situ staining, as 
performed above, may be more reliable than flow cytometry, though both use PI as an 
indicator of cell death, as cells require trypsinizing, washing and using centrifugation prior to 
analysis. Both methods use live cells (vital staining on a slide and flow cytometry on live 
cells) it was suspected that the slide staining method may deliver superior results as the flow 
cytometry results may be affected by loss of dead cells during the many manipulations, 
especially centrifugation.  
3.4.3 Cell death assessment of the MCF10A and MCF10A-NeoT cell lines by Flow 
Cytometry and PI staining. 
 
As the MTS results on lower concentrations of HYP did not show much selective 
cytotoxicity, only the effects of the 150 and 300 µM levels of HYP were assessed, but for the 
DAH and DMH compounds, four concentration levels (i.e. 4.8, 19, 75 and 300 µM) were 
assessed. Effects on cell numbers were assessed using the concentration of PI previously 
optimized in our laboratory for the cell lines used, except that only PI staining was performed 
as we found annexin V staining did not work well on our adherent cells.  
 
Compared to the DMSO control, HYP and DMH seem to show slight effects on the MCF10A 
cell line % cell death (Table 3.5). The DAH derivative shows induction of low levels of cell 
death at lower concentrations, in the MCF10A cell line but as the concentration increases the 
induction of cell death increasing marginally up to 150 µM and then decreases at 300 µM. 
The percentage of dead cells relative to controls, however, seems low possibly due to some 
stimulatory effect of the compound or less dead cells during cell preparation (especially 
centrifugation). Significance was not assessed due to low number of tests performed n=2, in 
triplicate (Table 3.4) and the preliminary range-find nature of the assessment of this novel 
method to our laboratory. These results seem to partially mirror the results from the MTS 
assay, however (Figure 3.8A, 3.8B and Table 3.3) indicating low toxicity of all compounds to 




Table 3.5: Flow cytometric determination of % live and dead cells in the two test cell 
lines post treatment. 
 
Standard Concentrations of the 
compounds(µM) 
 
Name of the 
compound 
MCF10A  Cell line MCF10A-NeoT Cell line 
% live cells % dead cell % live cells % dead 
cells 
 
4.8 Hypoxoside     
Dimethylhypoxoside 96.87 3.13 96.88 5.12 
Decaacetylhypoxoside 97 2.71 96.39 5.61 
19 Hypoxoside     
Dimethylhypoxoside 98.72 2.28 94.17 5.83 
Decaacetylhypoxoside 95.47 4.53 92.37 7.63 
75 Hypoxoside     
Dimethylhypoxoside 99.18 1.82 94.44 5.56 
Decaacetylhypoxoside 96.54 3.46 93.55 6.45 
150 Hypoxoside 94.63 6.36 94.83 5.17 
Dimethylhypoxoside     
Decaacetylhypoxoside     
300 Hypoxoside 96.88 3.35 93.49 6.51 
Dimethylhypoxoside 99.72 1.28 91.23 8.77 
Decaacetylhypoxoside 97.03 2.97 79.10 20.90 
 
The MCF10A-NeoT cells seem to show only minimal compound concentration-dependent 
increase in the cell death, except with the DAH derivative showing the highest % induction of 
cell death at 300 µM (20.9%). The DMH derivative, on the other hand, shows a % cell death 
of 8.77% and finally HYP, a 6.51% cell death. The % cell death induced by HYP and DMH 
(i.e. 6.51 and 8.77, respectively) are possibly not significantly different from the negative 
controls % cell death values i.e. DMSO control (9.28%) and media control (6.87%) (Table 
3.5), results largely confirmed by the MTS graphical and Duncan‟s analysis (Figure 3.8 A 
and B and Table 3.3), though these do not directly measure cell death. Therefore, the flow 
0 DMSO Control 95.64  4.36 90.72 9.28 
0 Medium Control 94.32 5.68 93.13 6.87 
0 Cyclohexamine 
Control 
32.40 67.60 76.40 23.60 
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cytometric results show no significant induction of cell death in either cell line, except with 
the DAH treatment at 300 µM in the MCF10-NeoT cells, with a % cell death induced being 
comparable with that of the positive control (cyclohexamine, 23.6%). Flow cytometry, using 
the method of single staining a cell preparation seems to need optimization or seems to be 
less sensitive than the optimized staining and MTS assay methods.  
 
3.4.4 Trypan blue hemocytometric cell count. 
 
As some treatments seem to have stimulatory effects (Figure 3.8), cell numbers of the treated 
and untreated cells were further assessed using the trypan exclusion method. This allows 
assessment of cell death, and, by manual counting, using a hemocytometer chamber the total 






































Figure 3.12: Total cell counts and the percentage dead cells (trypan blue stained) after 
treatment with different hypoxoside compounds.  
 
The MCF10A (A) and MCF10A-NeoT (B) cells were seeded in 25 ml TI flasks and allowed to 
grow o vernight. These ce lls were treated overnight with t he three hypoxoside compounds a t 
different concentrations as indicated in the graph. The cells were trypsinized, stained with trypan 
blue (dead cell blue), and the live (unstained) and dead cells were counted using hemocytometer 
in duplicate, n=2. Total live and dead cell counts were plotted in a stacked column showing the 
dead cells at the top red bar and the live on the bottom blue column. 
 
When the total number of cells (uncorrected) were counted post treatment with the different 
compounds a nd the cells that staine d blue (dead c ells i.e. late a poptotic or  ne crotic) were 




















































of compounds seem to stimulate an increase in cell numbers relative to the DMSO control 
group for  both cell li nes (MCF10A and MC F10A-NeoT), with the malignant cell li ne 
showing the gr eatest stimulation of proliferation with induction of  very li ttle cell de ath 
(Figure 3.12) . In the  MC F10A-NeoT t reatment with  the 19 and 300  µM c oncentrations of 
DAH, seems to show the greatest induction of cell death (evidenced by reduced cell numbers 




Figure 3.1 3: Cell d eath af ter tr eatment with three h ypoxoside c ompounds assessed 
using cell counts with trypan blue staining. 
  
 Cells were seeded an d allo wed to  g row o vernight and s ubsequently tr eated with th e three 
hypoxoside test co mpounds overnight. T o ass ess ce ll death a fter tr eatment with v arious 
concentrations of HYP, DMH or DAH, the cells were stained with trypan blue, which passes 
through the membrane of the dead cells and is excluded by the membrane of the live cells. The 
% dead cells (blue stained cells), expressed as a % of total cell counts, was calculated for both 
cell lines u sing hemocytometer an d co rrected f or th e DMSO-induced c ell death s een i n t he 
control (i.e. by subtraction of % dead cells on the DMSO control).  
 
Surprisingly, the 75 µ M concentration seems to kill proportionately about the same number 
of cells as the 150 µM concentration but it also seems to give rise to the greatest stimulation 
of cell proliferation in the MCF10-NeoT cells, implying a non-linear response (Figure 3.12). 
The trypan blue exclusion method reveals that all the compounds do not have a major effect 
of inducing cell death, however (Figure 3.13). Instead most  show growth stimulatory effect 
on both cell lines, with the greatest effect on MCF10A-NeoT cells (Figure 3.12). As in the 
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case of the flow cytometry method, cell numbers and % cell death are only determined after 
trypsinization, washing and using centrifugation (a point at which especially dead cells may 
be lost). 
 
When looking at the portion of dead cells relative to the total cell count for each 
concentration or the various compounds (i.e. % cell death or dead cells expressed as a % of 
the total cell number for each treatment group), it seems there are no major compound-
specific or concentration-specific effects observed for induction of cell death in the MCF10A 
(Figure 3.13), with most except the 300 µM concentration, apparently depressing the relative 
percentage cell death in the MCF10A. This does not seem to be due to proliferation-
promoting activity, as seen with treatment of MCF10A-NeoT cells with most compounds 
(Figure 3.12, as evident in increased cell numbers in MCF10A-NeoT cells) as the compounds 
seem to have a lower proliferation-promoting effect on the MCF10A cells (Figure 3.10A and 
3.12A). This seems to support the Duncan‟s test conclusion on the metabolic activity for the 
MCF10A but contradicts PI staining results and the results of the trypan blue staining due to a 
lower sensitivity of the two methods for detection of cell death. Despite the apparent low 
sensitivity of trypan blue for detecting cell death, the HYP is seen to have a slight 
concentration-dependent effect of increasing cell death in the MCF10A-NeoT cells relative to 
the DMSO control, as do the DMH and DAH (Figure 3.12 and 3.13). This seems to agree 
with the supravital PI staining results for induction of cell death (Figure 3.11B).  
 
In the MCF10A cells, the DAH derivative also has only a slight concentration-dependent 
effect especially at 300 µM (Figure 3.13). The overall effect of the three compounds in 
inducing cell death does not seem to be significantly different according to the trypan blue 
staining test except that the total cell counts in the MCF10A-NeoT cells seem significantly 
depressed at 19 µM (and possibly 150 µM which was not tested) and the 300 µM DAH 
(Figure 3.12).  
 
Comparing % cell death determined using trypan blue staining for dead cells and total cell 
counts and the flow cytometry results, the HYP, DMH and even DAH produced similar 







Table 3.6: Comparison of the PI Flow cytometric test with the Trypan blue test results 
 
      % Cell Death   
 
Flow 
Cytometer Trypan Blue 
Concentration (µM)      10 A     NT 
 
    10 A       NT 
 




















































Similar results are seen in the MCF10A-NeoT cells, with % cell death at all concentrations 
relative to the controls not significantly affected except at the 300 µM DAH treatment level 
for both cell lines where cell death increases (Figure 3.13 and Table 3.6). Though the 150 µM 
level DAH was not assessed, this result would be anticipated to be similar to what was seen 
in the Duncan‟s analysis of the MTS values and with the 300 µM concentrations. 
 
From the flow cytometry cytotoxicity test results, one may conclude that the three 
hypoxoside compounds have no significant or selective effect on cell death in both cell lines, 
except for the 300 µM DAH compound on the MCF10A-NeoT cells (Table 3.5). Trypan blue 
staining seem to indicate a slightly more selective induction of cell death in the MCF10A-
NeoT cells after treatment with all compounds and the 300 µM DAH concentration relative 
to the media control (Figure 3.12, 3.13 and Table 3.5). This agrees with the AO/PI supravital 
staining result trend, though the trypan blue staining method does not seem to be as sensitive. 
Some selective cytotoxicity on the MCF10A-NeoT cells seems to be observed, especially 
with the 300 µM HYP, 300 µM DMH and 300 µM DAH using trypan blue (Table 3.6). 






In the current range-find experiment for the assessment of the effect of 3 compounds (i.e. 
HYP, DMH and DAH) on the normal MCF10A cell line and its VAL-12 c-Ha-ras derivative, 
the MTS metabolic activity assay results, together with the Duncan‟s multiple range test 
analysis, indicates statistically that the DAH compound, at a concentration of 150 and 300 
M, and none of the other compounds, have an overall rigorously statistically validated 
selective effect on the metabolic activity of the premalignant test breast epithelial cell line 
(with no major effect on the normal MCF-10A breast epithelial cells).  
 
After performing this study, the simultaneous post treatment assessment of cell count, and a 
Duncan‟s multiple range test analysis of MTS metabolic assay results, is considered essential. 
Though the MTS assay proved a useful indicator of metabolic activity, visual inspection of 
the graphical representation of results, without Duncan‟s analysis of results and without cell 
counts, would seem to indicate that any level of DAH and any higher concentration of HYP 
and DMH would be an optimal choice for treatment of Ha-ras-related breast epithelial cell 
malignancies. Though this is also indicated by the supravital adherent cell staining technique 
using PI (Zamai et al., 2001), this course of action is not supported by the Duncan‟s analysis, 
nor cell counts (which indicate that all compounds support premalignant cell proliferation, 
especially at lower concentrations).  
 
Surprisingly, though flow cytometry has been pronounced (above) to lack sensitivity, it too 
supports the fact that only the 300 µM DAH (and possibly the 150 µM DAH, if it had been 
assessed by flow cytometry), would be suitable for the selective therapeutic application in the 
treatment of premalignant and possibly malignant breast cancers. 
 
Only with multiple range analysis of the MTS results was the 150 and 300 M range 
unequivocally advocated. Without the simultaneous assessment of cell numbers, further trials 
(including clinical trials) using other hypoxoside compounds at various levels may be 
attempted without being aware that the hypoxoside derivatives, including the DAH 
derivative, at levels below about a 150 M limit, may have the undesirable effect of inducing 
proliferation of premalignant (cancer) cells. Total cell counts and, though insensitive, the 
Trypan blue staining method, and the Duncan‟s multiple range analysis, seem essential co-




The supravital staining method used was useful in confirming the lack of toxicity of the HYP 
and its derivatives, on the normal breast epithelial cell line, and may indicate the incipient 
death of the premalignant cell line, post treatment with all hypoxoside compounds, at all 
levels, as indicated by results of supravital adherent cell staining (being highly sensitive). 
Such staining results may portend a massive cell death event which may manifest itself if the 
24 hour test exposure time were extended. The exposure time should, therefore, be extended 
and another method besides the PI staining method should be investigated to validate 
induction of cell death. The more long term outcome of exposure to the test compounds, 
should be investigated. 
 
If the current conclusions are supported by such further investigations and additional tests for 
the induction of cell death, the trypan blue method, together with the MTS assay, total cell 
counts and the Duncan‟s analysis of MTS results and a 24 hour exposure to test compounds, 
























GENERAL DISCUSSION, CONCLUSION AND FUTURE WORK. 
 
4.1 GENERAL DISCUSSION 
 
Naturally available substances are important in everyday life. These substances are derived 
from various sources which include micro-organisms, marine creatures, animals and plants. 
The natural products are used in different fields of endeavor, such as in pharmaceuticals as 
drugs, and in agriculture as pesticides to manage insects and other pests. These may be 
associated with fewer risks compared to the synthetic products that are generally less 
biodegradable. They may be used in the food industry, in beauty industries in perfumes and 
body lotions and in other industries involved in producing synthetic products from bioactive 
components. The use of natural products requires the isolation and identification of active 
components and knowledge of their structure. Such information can be used to assist in the 
derivatization and hence synthesis of natural compounds with increased activity for specific 
purposes.  
 
The efficacy of rooperol for the treatment of cancer is controversial as there has been little 
success seen in clinical trials (Albrecht et al., 1995a; Albrecht et al., 1995b; Boukes, 2008; 
Boukes et al., 2010; Boukes and Van de Venter, 2011). For this reason, in the current study, 
derivatives of hypoxoside that may have greater activity against premalignant (and hopefully 
malignant) breast cancers were investigated. Few studies have been carried out on the role of 
hypoxoside or rooperol per se (Smit et al., 1995) and no studies have been performed on the 
DAH and DMH derivatives previously synthesized by Bettolo et al. (1982), i.e. the 
derivatives chosen for the current investigation. Pure hypoxoside and the DAH and DMH 
derivatives were prepared and analyzed for the selective cytotoxicity on the normal 
(MCF10A) and premalignant cell lines (MCF10A-NeoT).  
 
The problem with such a study is that a wide variety of methods are available for assessing 
the selective toxicity and induction of the safe form of cell death (or apoptosis) by such 
compounds. Due to time constraints, only four different methods could be assessed in the 
current study (i.e. (i) the MTS assay for the monitoring of effects on metabolic activity, (ii) 
AO/PI supravital staining of adherent cells, and fluorescence microscopy, (iii) supravital 
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staining with PI for flow cytometric determination of % cell death, and (iv) the trypan blue 
staining methods for checking the assessment of % cell death using a hemocytometer and 
total cell count).  
 
The term apoptosis is used to describe a number of physiological, biochemical and molecular 
changes exhibited by a cell that is about to die in a programmed way (as mention in Chapter 
1) (Darizynkiewicz et al., 1992). The induction of apoptosis is usually the goal when testing 
an anticancer drug and there are a variety of methods used to assess the characteristic 
changes. The most consistent target for analyzing the induction of apoptosis is an 
examination of the membrane integrity or induction of permeability in the membrane of the 
target cell, a disrupted membrane being a feature of apoptotic cells. Therefore, 
fluorophores/dyes such as PI and DAPI, that are not usually able to enter inside non-apoptotic 
cells and stain the nucleus due to their intact nature, are used (Van England et al., 1996). 
 
Unfortunately, the different dyes used in assessing apoptosis or programmed cell death or cell 
viability are used at a variety of different concentrations and with a variety of different 
exposure times. Choice of protocol is difficult even if a common key dye used in this context, 
is selected. Supravital staining gave rise to results that could not be well reconciled with the 
an overall interpretation of the results of the current study.  
 
Widely differing PI procedures are used in staining cells for either flow cytometry or 
fluorescence microscopy for cell death assessment. A review article by Darzynkiewicz et al. 
(1992), for example, gave the final concentration of PI to be used for supravital staining as 13 
µg/ml, with cells being stained for 30 minutes after harvesting (Darizynkiewicz et al., 1992). 
Longer exposure to allow PI to efficiently enter apoptotic cells and stain the nucleus was 
mentioned to be more desirable. 
 
For this reason, the Zamai et al. (2001) protocol using supravital staining of cells (i.e. without 
fixation) and a higher concentration of PI (50 µg/ml) for 30 minutes was considered. 
Increasing the incubation time (to 4 h) and staining with higher concentrations (i.e. 50 µg/ml) 
of PI was also claimed to be necessary for staining apoptotic cells efficiently (Zamai et al., 




In another study on the anticancer activity of a certain compound, using supravital MCF7 cell 
line and AO and PI staining at much lower levels for much shorter periods was advised. 
Concentrations of AO and PI used were 1 µg/ml and 12 µM concentrations, respectively, 
with only 5 minutes exposure time used for AO staining and these measures gave 
reproducible results (Visagie and Joubert, 2011). Another study using a lower concentration 
of dyes and shorter exposure time involved Hoechst (HO) staining optimal at 20 µM for 20 
minutes at 37oC, AO optimal at 0.67 nM at 37oC for 10 minutes and PI optimal at 3 nM for 5 
minutes at 37oC (Foglieni et al., 2001). This study outlined the importance of optimising the 
staining procedure for the specific cell line one is using. In this study cells were fixed prior to 
staining (assessment of cell death) and it was reckoned that the discrepancy of the result was 
due to that (Foglieni et al., 2001). It was, decided to use the method of Zamai et al., 2001, 
however, as the method was claimed to facilitate detection of living (PI negative), apoptotic 
(PI dim) and necrotic cells (PI bright) and also used supravital cells as in the current study 
(Zamai et al., 2001). The subsequent apparent observed over-sensitivity of the detection of 
cell death and the lack of sensitivity of flow cytometric assay, however, were disappointing 
and need re-investigation. Results may, however, be explained as follows:  
 
Early studies of flow cytometry-based PI assays and PI staining of adherent cells included an 
RNase treatment step, due to the fact that PI does not only bind DNA but any double stranded 
nucleic acid, such as RNA. A RNase pre-treatment step was, therefore, included to reduce the 
number of falsely PI-stained cells (Rieger et al., 2010). This step was omitted in the current 
study, as over 99% of published data generated with PI staining have been generated without 
pre-treating cells with RNAse. Increased production of proteins induced in the Ras-activated 
MCF10A-NeoT cells, however, may result in increased cellular mRNA, relative to that found 
in MCF10A cells and induced false positive staining for apparent cell death (PI positive 
staining). A lack in RNAse pre-treatment, may, therefore, have resulted in the unanticipated 
positive PI staining pattern seen in the ras-transfected cells in the current study. The effect of 
RNAse pre-treatment of MCF10A and MCF10A-NeoT cells, prior to staining should, 
therefore, be investigated. Supravital AO/PI staining has also been reported to only give 
reproducible results only when AO is applied to live cells before PI (Foglieni et al., 2001). In 
the current study, both dyes were applied simultaneously and this might also have influenced 




The flow cytometry assay results, using PI staining for detection of cell death, also did not 
confirm fluorescence microscopy results. If the positive results seen, post-treatment, on 
staining of adherent cells was “real”, this discrepancy in results may be due to the different 
staining protocols used or due to the fact that flow cytometric assays may give false negative 
results, if apoptotic cells stain weakly. These cells may subsequently be erroneously 
classified as viable cells if the detection threshold (sensitivity) of the flow cytometer is set too 
high (Darizynkiewicz et al., 1992). This may also account for the apparent low detection of 
apoptotic cells in the current study. 
 
When considering the supravital staining results, the possibility exists that the PI may react 
more avidly with the MCF10A-NeoT cells than the MCF10A cells, due to distinct intrinsic 
characteristics of the transformed cell and its membrane. The concentration of PI and length 
of time required for staining may need to be individually optimized for each cell line due to 
such differences, and differences in the cytoplasmic pH of the MCF10A-NeoT cells 
(unpublished results) which may also influence the intensity of PI staining. Control results 
seem to discount this theory, however, as both positive and negative controls deliver 
distinctive positive and negative results. The final concentration of the AO and PI dye used in 
supravital staining was 5 µg/ml per dye which is much less than is recommended by Zamai et 
al. (2001) (50 µg/ml), but the low concentrations gave more than adequate positive PI 
staining results and good positive and negative staining results for controls.  
 
For flow cytometric studies, a similar problem was encountered. PI labeling was used at 5 
µg/ml concentration and the exposure time was 45 minutes. Annexin V together with PI 
staining is often used to differentiate between live, apoptotic and necrotic cells, based on cell 
membrane integrity and the binding of annexin V to phosphatidylserine. Phosphatidylserine 
is usually present on the inner surface of intact, viable cells, but is present on the outer 
surface of apoptotic cells (Rieger et al., 2010). It would have been most convenient if such a 
confirmatory staining procedure could have been used in the present study. Binding of 
annexin V, however, requires the presence of fairly high levels of calcium. This is usually 
added to the labeling buffer and, as with our cells, this often resulted in dislodgement and loss 
of adherent cells. For this reason, it has been recently reported that annexin V is only suitable 
for labelling non-adherent cell lines (Zamai et al., 2001) and the annexin V method was not 




Cells were also stained supravitally to avoid the negative effect of fixation on the cell 
membrane. The low level of detection of cell death using the flow cytometric PI staining 
method may be due to the low concentration of PI used, or the length of exposure to PI, 
however, compared to the one recommended by Zamai et al., (2001) for efficient assessment 
of apoptosis (i.e. 50 µg/ml for 4 h). The method used was, however, previously optimized for 
the cell lines used in this study as positive and negative controls seemed to indicate that, for 
detection of live and apoptotic cells, the system was working optimally in the flow cytometry 
as in the supravital staining methods. For this reason it seemed that differences in staining 
protocols used for these two analyses should not be of concern. 
 
At the commencement of the study, supravital staining for fluorescence microscopy using 
stains with AO and PI seemed to be the most convenient, direct and reliable methods to use 
as no fixation step was employed and no dislodging of the adherent cells and subsequent 
manipulation was required (Coder, 1997). This would obviate any loss of specific cell 
populations during centrifugation procedures necessary for cell preparation for flow 
cytometry, trypan blue staining and cell counts. Centrifugation is potentially a great problem 
as damaged or apoptotic cells more easily aggregate and may be removed as clumps that will 
not re-suspend after centrifugation.  
 
The MTS assay too was considered an optimal choice of technique, as here too there was no 
dislodgement of cells which may cause disruption of the cell compartmentalization and loss 
of damaged cells by aggregation (Coder, 1997). This method also detects metabolic activity 
related to viability, so represented a complementary method to validate the metabolic related 
results. These two methods were, therefore, considered the most important methods for use in 
the current study.  
 
When looking at the proliferation assays graphs for the optimization of MCF10A and 
MCF10A-NeoT cell numbers to be used in the MTS assay, to check the linearity and 
sensitivity of both cell lines, the graph produced for the MCF10A-NeoT cells clearly shows 
that the two cell lines react differently with the MTS tetrazolium salt. The normal (MCF10A) 
cell line results showed a greater sensitivity to cell number. This surprisingly was not the case 
with the premalignant (MCF10A-NeoT) cell line, where a lower response to changes in cell 
numbers was observed. This may be explained by the Warburg metabolism of the cancer 
cells, and the possible decreased conversion of MTS tetrazolium salt by the MCF10A-NeoT 
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cells, due to an altered metabolism of the premalignant cells. In spite of this, the MTS assay 
results revealed the marked selective proliferation of cells with most treatments but 
depression of the metabolic activity in the MCF10A-NeoT with DAH treatment. This showed 
the most significant (p < 0.001) depression of metabolic activity compared to the MCF10A or 
any other test compound.  
 
The MTS assay is a widely used method, widely assumed to assess the level of cell death 
induced when it actually tests effects on metabolic activity. Such a parameter may be only 
vaguely associated with cell number. While the MTS assay is normally known to test cell 
viability, this is not factually accurate, because cells can be metabolically depressed without 
necessarily dying. Cells may also be depressed metabolically for some time and later recover 
fully. Assessment of cell counts is, therefore, essential as the MTS assay is also affected by 
cell number. This became startlingly clear in the current study, where, without associated cell 
counts, metabolic depression may have been taken to mean that cells were dying with 
treatment, where, in fact cell proliferation was being induced. This is a startling novel finding 
of this study. 
 
The MTS assay, on the other hand, is a convenient assay being simple, quick, and 
inexpensive and more importantly, it gives a measure of cell viability without disturbing cells 
in culture i.e. without the requirement for damaging trypsinization and other procedures 
which may introduce errors (Huang et al., 2004). This assay can give fairly early stage 
indication of incipient cell death, but it is really important to interpret results using powerful 
multiparameter programs such as the ANOVA post hoc Duncan‟s multiple range analysis and 
at least a cell count. Without the Duncan‟s analysis and cell counts, the MTS assay results are 
difficult to accurately interpret.  
 
Where PI staining for indication of cell death proved problematic, the crude and simple 
trypan blue viability staining method, using hemocytometer total and trypan blue stained cell 
counts, for a rough assessment of % cell death, proved almost adequate. The trypan blue 
assay reflected similar results as those seen with the PI flow cytometric assay i.e. no 
significant killing of the normal cell line and only a marginal concentration-dependent low 
level of killing of the abnormal cell line at low levels of DAH. More significant killing, 
however, was seen at 150 and 300 M levels of DAH. The effect of treatments in increasing 
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proliferation of normal, and, more, markedly the abnormal cell line, was, however, 
surprising. This appears to mean that, even with treatment with the DAH compound that 
shows selective toxicity in the premalignant cells, the concentration of DAH needs to be 
approximately 150 M or more to be effective in controlling premalignant cell proliferation.  
 
The aim of the current study was to: 
 Isolate and purify hypoxoside from the Hypoxis hemerocallidea, through 
extraction of corms with ethanol and further isolation with HPCL pre-packed 
reverse phase column – this was achieved. 
 Prepare two derivatives from pure hypoxoside through methylation and 
acetylation, resulting in a dimethyl and a decaacetyl derivative, respectively - this 
was achieved.  
 Confirm the purity of hypoxoside and the derivative using NMR spectroscopy and 
HR-MS - this was achieved. 
 Establish an inexpensive, rapid, high-throughput method for the preliminary 
assessment of the selective effects and cytotoxicity of the prepared compounds. 
This was assessed using cell counts, metabolic assessment (MTS assay) and 
imaging using flow cytometry and fluorescence microscopy, using dyes 
(especially supravital staining with propidium iodide claimed to be useful in 
distinguishing live from early apoptotic and late apoptotic/necrotic cells). It is now 
considered that this has been achieved. The system that seems to work well is the 
use of the Trypan blue and total cell counts, together with the MTS assay, and the 
Duncan‟s analysis of the 24 hour exposure MTS results of the test cell lines. This 
seems to constitute an optimal system for drug screening. 
4.2 CONCLUSION 
 
The preliminary data collected, suggests that one may not make valid conclusions on 
assessment of cytotoxicity with only the metabolic activity test (MTS assay) without 
performing the Duncan‟s multiple range test on the MTS results and cell counts with trypan 




Analysis of chlorofom extracts of corms of various Hypoxis species and cancer cell toxicity 
studies showed that H. hemerocallidea  extracts had the highest concentration of hypoxoside 
compared to other species (Boukes et al., 2008), but had the lowest anticancer activity 
(Boukes et al., 2011). Such extracts, however, were impure, containing various sterols and 
sterolins. This suggests that hypoxoside/rooperol activity has a synergic effect with other 
unknown compounds such as sterols and sterolins present in impure test extracts (Boukes et 
al., 2011).  
 
Our data on purified hypoxoside, however, suggests that purified HYP from H. 
hemerocallidea (converted to rooperol by deglycosylation, as indicated in Figure 1.2) has a 
protective and proliferation-stimulating effect in both normal and premalignant breast 
epithelial cells. The DMH and DAH derivatives represent methyl and acetyl derivatives of 
both the sugar groups and the 3‟ and 3” hydroxyl groups on the hypoxoside molecule (Figure 
2.3). Just as the hypoxoside is converted to the aglycone in vivo to produce rooperol, the 
DMH derivative would be anticipated to be similarly deglycosylated to yield the 3‟,3”-
dimethyl derivative of rooperol. This conclusion seems supported by the fact that the methyl 
derivative (DMH compound) seems to have a similar protective and proliferation-inducing 
effect, like rooperol.  
 
The acetyl derivative, DAH, on the other hand, is substantially less polar than HYP and 
DMH. Although it can be envisaged that DAH is eventually metabolized to rooperol by the 
action of esterase and glucosidase enzymes, this may be a slower process. This would explain 
the seemingly significant, selective effect of the acetyl derivative, at a concentration of 150 
and 300 M, on the premalignant breast epithelial test cell model. This compound may, 
therefore, have similar action on other Ras-related malignancies and this possibility should be 
further explored.  
 
4.3 FUTURE STUDIES 
 
 For all cell death assessment procedures carried out in the current study, the treatment 
exposure period of the tested drugs should be increased to better observe their long 
term effects on the cancer cell model used. Tests should also be extended to other cell 
lines of other cell types. 
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 In the AO/PI staining procedure, the two dyes should not be applied simultaneously- 
the AO should be applied first and then PI, as the simultaneous application has been 
reported to give erroneous results. 
 The flow cytometric PI staining procedure can be improved by coupling the PI with 
another dye, which may better detect apoptotic cells, as the PI “dim-staining” 
apoptotic cells may be erroneously miss-classified apoptotic cells as viable in flow 
cytometric analyses. 
 As rooperol has been reported to have a strong antioxidant activity, the antioxidant 
activity of the derivatives (i.e. DMH and DAH) prepared in the current study should 
be further investigated. 
 The mode of action of the DAH in it‟s selective toxicity to the premalignant cancer 
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APPENDIX A: NMR SPECTRA AND HR-MASS SPECTRA Plate 1: lH NMR of hypoxoside 
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Plate 9: HR-MS of dimethylhypoxoside. 
~
6' OH O-CH3 
5' ~' o 0 3'-...;:: 'l 
4' OH I 5' ...-:; l ' 2 
Oli..' , 0' ,;:/ 1 
OH 
Single Mass Analysis 
Tolerance = 4 .0 PPM I DBE: min = -1 .5 , max = 50.0 
Element prediclion: ON 
Number of isotope peaks used for i-FIT = 3 




l ' OH 
2" /3M:[M HO 4
M 
I 
" 0 0 
2" 3" 





3 formula(e) evaluated with " results Within limits (all results (up to 1000) for each mass) 
Elements Used: 
C: 30·35 H: 35..40 0: 10- 15 Na: 0·1 
Prof. Drewe S 





6.5~ .23 33 
663.2521 
TOF MS ES. 
9.91.+003 
6' 6 9577 00 1.2744 
O,~~6~5~1~.8T6~29~~65T3~.2~4~60~6~~~.~9~53~8~.6r5~5~. ~87~3~~o~·~~~~;-~~~~~6~60~.2~2~90~~Lr~6~62~.~27~2~9 ~~~.~. ~.-~.~-~.~~~ ,- mt: 
oM '~'n 664.9519 
652.0 6~.0 656.0 658.0 660.0 662.0 664.0 
}E.n~.-'·i\"UIt\ ; 1.5 
~·faKi..rnum : 5 . 0 4 . 0 5 0 .0 
}1~::) ~ Calc . H.:t,:J,:I :":\D~ N 'M DBE i.-FIT i-FI T (No ;:"rn ) FOrr.li.u lu 
657.:153 657.:159 - 0 . 6 - 0.9 1: .5 91 . 5 0 . 0 C31 03 8 014 Na 
-N ..,. 












j! (f i ( 
I I I I I I , , I 
,,,-,,,~-,,---_ ...... __ --,J , ~~ )tI.~i )UI L.. . 
7 .5 7 .0 
.- --, ~ -·~-'--~-~~-·-'---T·--~- · --·r-·- ·-~-· -r-..... -~· "'-~-"---- "'''''-'-~'''---'---~'''-.---'-,---~.' T-·---~'-· ·-· - '- ' T'- '-
•. 5 6.0 ppm 5.5 5.0 4.5 4.0 3.5 3.0 
[;1;1 
I..; 1~("1 "i1~1 :l! _~ N , "" ! "" I '" I'd "' j i"i '~l :!il '........ ... 
I • 
i ~1 :1 t ~ ~ :_ 1 
2.5 2.0 1 .5 
J • .. !JI.\~~ I 










Single Mass Analysis 
Tolerance = 4 ,0 PPM I DBE: min = -1 ,5. max = 50,0 
Element prediction : Off 
Number of isotope peaks used for i-FlT = 3 




2 lormula(e) evaluated with " results within limits (all resuHs (up to 1000) for each mass) 
Elements Used: 
c: 45-50 H: 50-55 0: 20-25 Na : 0-1 
Prof. Drewes. 


















- 1. 5 
4.0 50 . 0 
FPM DBE i-FI T i-FIT 












APPENDIX B: FLOW CYTOMETRY RESULTS. 
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KEY FOR FLOW CYTOMMETRY OUTPUTS 
Samnle code Comnound tvne Concentration 111M Cell Tvne 
A chx contrfCCYclohexamidef Positive control nt (MCFIOA-NeoT 
B medium conO'I (cell culture media) Negative control I nt MCFIOA-Neo'n 
C hvn "hvnoxoside) 150 nt MCFIOA-NeoT) 
D hvn hVDOxoside) 300 nt MCFIOA-NcoT 
E dmh (" dimethvI hVOOxoside 4.8 nt MCFIOA-NeoT 
F dmh dimethyl hvnnxoside 19 nt MCFIOA-NeoT 
G dmh dimethvl hvnoxoside 75 nl MCFIOA-NeoT 
H dmh dimethvl hvooxoside 300 nt MeFIOA-NeoT 
I dah DecaacetVi hViiOxoside 4.8 ot MeFIOA-NeaT 
J dab Decaacety! hvnnxoside 19 nt (MCFIOA-NeoT) 
K dab Decaacetvl hvnoxoside 75 nt IMCFIOA-NeoT) 
L dab Decaacetvl hvooxoside 300 nt IMCFIOA-NeoT) 
M medium contrTI cell culture medii) Nmtive control I 10. (MCFIOA 
N dmso contrl (DMSO controll Ne£ative control 2 lOa (MCFIOAl 
0 chx contrl (cvclohexamide Positive control lOa (MCFIOA 
p hvn lhvnoxosidel 150 10alMCFIOA 
dmh(dimethVl hvooxoside) 4.8 lOa (MCFIOA 
R hVD (hVDOxosidel 300 lOa (MCFIOA 
S dmh (dimethvl hvnoxoside 19 lOa MCFIOA) 
T dmh {dimethvl hvnoxoside 75 lOa MCF IOA 
U dmh dimethvl hvnoxoside 300 10. MCF IOA 
Y dah (DecaaceLYi hVDoxoside 4 .8 10. MCFIOA 
W dah (DecaacP.1v1 hvnoxoside 19 lOa MCFIOA 
X dah (Decaacetvl hvnoxosidc 75 l Oa MCFIOA) 
y dab lDecaacctvl hvnoxoside 300 10. MCFIOA) 
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